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Abstract
Background: Inflammatory Bowel Disease (IBD) is an immune-deficient gut diseases 
complex [Crohn’s Disease (CD) and Ulcerative Colitis (UC)] which cause serious 
digestive problems from prolonged inflammation. A multitude of immunological, 
microbial and environmental reasons have been named as its causative agents although 
its true aetiology is still unknown. There is no known definite treatment regime, nor a 
permanent cure has yet been established for these serious chronic illnesses in the gut. 
This study has attempted to investigate the influence of the C-C Chemokine Receptor 6 
(CCR6) and its sole ligand C-C Chemokine Ligand (CCL20) as a potential therapeutic 
target for IBD given the important immunological role played by this chemokine pair. 
The immunomodulatory behaviour of the CCR6/CCL20 axis on multi-system 
pathophysiology was investigated at two clinically significant time points, using a Ccr6-
deficient mouse model of spontaneous colitis. Methods: Four groups of mice, [(i) 
C57BL/6J which was the Wild Type abbreviated as WT and having (Winnie +/+, Ccr6 +/+) 
genotype (ii) homozygous Ccr6-/- mutant  of the WT having (Winnie +/+, Ccr6-/-) 
genotype (iii) Winnie x Ccr6 -/-, the double knockout experimental model derived from 
the WT background (denoted by Winnie m/m, Ccr6-/-) and (iv) Winnie, also derived from 
the WT background, having the (m/m, Ccr6+/+) genotype] were utilized and (1) colonic 
inflammatory parameters, (2) colonic histology, (3) histology of spleen, kidney and liver 
(4) T and B lymphocyte quantification in the spleen and mesenteric lymph nodes (MLN)
by flow cytometry, (5) colonic CCL20, phosphorylated phosphoinositide – 3 – kinase 
(PI3KP) and phosphorylated protein kinase B also known as (AktP) expression by 
immunohistochemistry, and (6) cytokine expression in the colon by real time – 
polymerase chain reaction (RT-PCR) were evaluated. Results: CCR6 influenced 
upregulation of inflammation during murine colitis in the gut, spleen and liver while 
renal histology remained unaffected. Marked focal lobular inflammation with reactive 
nuclear features were observed in hepatocytes and a significant neutrophil infiltration in 
red pulp with extra medullary hemopoiesis existed in the spleen. These changes were 
xx 
considerably reduced in the gut, spleen and liver of Winnie x Ccr6-/- [also known as the 
Ccr6-deficient-Winnie] with elevated goblet cell numbers and a conspicuously high 
mucus production in the colonic epithelium. In its spleen, the splenic lymphocyte 
percentage during early inflammation remained static but declined considerably 
towards the acute inflammatory stage compared to the WT, indicating decreased 
lymphocyte egression. The reverse of splenic hemopoiesis was seen in the MLN of the 
same model which had suppressed lymphocyte presence at 8 weeks which was restored 
with increased presence during acute disease.  Cytokine expression in the Winnie x Ccr6-
/- was below that of Winnie in all the cytokines tested. As an effect of CCR6 deficiency 
during chronic colitis, Winnie x Ccr6-/- produced upregulation of AKTP and 
downregulation of PI3KP in its molecular signalling apparatus, compared to those of 
Winnie. Conclusion: CCR6/CCL20 are known to produce detrimental effects in the gut 
and this is further substantiated by our study. We report inflammation and tissue injury 
in the spleen and liver during chronic colitis in the Winnie model for the first time. 
Results indicated that Ccr6 deficiency in the experimental colitis model contributed 
towards ameliorating colitis. Consequently, they displayed reduced inflammation in the 
gut, spleen and liver. These findings demonstrate an intricate networking role for CCR6 
in pre-clinical immune activation, which was substantially diminished in Winnie x Ccr6-
/- and need clinical investigation to determine whether it could provide newer clinical 
therapies in colitis.  
1 
1.0 Introduction 
1.1 Inflammatory Bowel Disease 
1.1.1 Epidemiology and Economic Impact 
Inflammatory bowel disease (IBD) is  a complex, chronic gut disease comprising two 
concordant phenotypes; Crohn’s disease (CD) and ulcerative colitis (UC) (1). Both CD 
and UC feature a relapsing–remitting disease course with colectomy as the final 
treatment option and a high risk of developing colorectal cancer (CRC) (2). Symptoms 
of both the disease phenotypes can include rectal bleeding, abdominal pain, tenesmus, 
urgency to evacuate, prolonged intermittent diarrhea, anorexia, fatigue, and weight 
loss (3). Extraintestinal manifestations include arthritis, skin rashes, dysfunction of the 
eyes, liver and kidneys (4). The severity of the symptoms varies from mild to severe. 
The most common complication of CD is the blockage of the intestine due to swelling, 
which results in the thickening of the bowel wall (5). Afflicted persons often encounter 
problems related to malnutrition, triggered by poor nutrient absorption (6). 
CD and UC can be differentiated by their location in the gastrointestinal tract, with 
severity of inflammation appearing in the intestinal wall and the specific nature of  
pathophysiology (7). CD is a chronic, transmural, segmental, inflammatory disease 
that involves any part of the gut from mouth to anus but mostly affects the terminal 
ileum (8). CD is characterized by mucosal granuloma and can be complicated by the 
development of fistulas and strictures (9). UC is a chronic, inflammatory disease 
which affects only the mucosa of the colon and the rectum (10). 
Studies also show that IBD most commonly presents in young adults aged between 
15 and 29 years of age. Another prominent age group are those aged between 60 and 
70 years (11). IBD causes severe morbidity in young adults at their most productive 
age (12).  The disease itself places a heavy burden on the patients by causing 
psychological distress, annihilating career objectives, instilling social stigma and 
degrading their quality of life (13).  
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Population-based studies reveal IBD to be a global disease of the 21st century, with 
the highest prevalence in Europe and North America (14). A 2016, USA-based study 
reported an increase of 1.3% in IBD prevalence rates, and showed that the disease was 
more common in people who were unemployed, living in poverty, and lacking a high 
school education (15). Increasing rates of IBD have been shown in several newly 
industrialized countries in Asia, Africa, South America, and the Middle East since the 
1990s (16). 
A recent population survey identified Australia as also having the highest prevalence 
of IBD alongside Canada, Denmark, and New Zealand, with CD being more common 
than UC in the Australian population (17). The data also showed that IBD is becoming 
more severe and more complex in Australia, also with a projected estimate of 100,000 
patients in 2022 (18). Among the Australians surveyed, factors such as smoking, 
childhood immunological events, namely, tonsillectomy or chickenpox, and frequent 
intake of fast food, were factors associated with the high risk of developing IBD, while 
frequent caffeine consumption and pet ownership provided protection against 
developing the disease (19). Another survey had estimated the cost of IBD  to the 
Australian State, for 242 Australian patients, in their first 12 months from diagnosis,  
was over 2 million Australian Dollars (20). 
1.1.2 Aetiology and Pathogenesis 
The aetiology of IBD is not completely understood yet, but it is commonly attributed 
to the gastrointestinal (GI) tract stimulation by excessive and abnormal adaptive 
immune responses via induction of pro-inflammatory cytokines (21). Such immune 
activation is produced against the 100 trillion or so luminal microbial flora inhabiting 
the intestine, which spans about 200–400 m2  (22). Dysregulated innate and adaptive 
immunity followed by microbial dysbiosis, due to the disruption of the mucosal 
barrier, which exposes persons to numerous luminal antigens, play a significant role 
in the disease development (23). Decreased rates of IBD in rural environments and 
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increased rates of IBD in overly clean environments too, have been reported, while 
enteric infections may trigger the onset in settings such as refugee camps (24) (25).   
IBD is considered as a group of highly complex,  heritable diseases, where more than 
200 genetic loci including, Nucleotide-binding oligomerization domain-containing 
protein 2 (NOD2), Autophagy related like 16 gene (ATR16GL), X-Box binding protein 
1 (XBPI), Interleukin twenty three  receptor (IL23R), Signal transducer and activator 
of transcription 3 (STAT3), Janus Kinase 2 (JAK2) and C-C Chemokine Receptor six 
(CCR6), have been implicated as predisposing factors  (26). Recently, heritability was 
endowed with only a 25% probability,  being recognized as the cardinal factor causing 
IBD, because a multitude of environmental factors are also now held accountable (27).  
Multiple causative factors, newly defined as the “exposome”, consisting of all the 
environmental contributory agents, are now implicated in IBD (28). These include the 
gut microbiota (both commensal and pathogenic), excessive usage of antibiotics, 
nutrition, smoking, industrialization with more exposure to pollutants, a westernized 
lifestyle, poor access to hygienic toileting, sleep disorders, anxiety and depression, 
appendectomy, exposure to bright sunlight, increased vitamin D and the use of oral 
contraceptives (29).  
Rather than being attributed to entirely genetic predisposition and microbiome status, 
more recent explanations focus on dysfunctional signalling pathways. One of these 
pathways involved endoplasmic reticulum stress (ER-stress)-induced apoptosis, due 
to the unfolded protein response, which had resulted in the autophagy of Paneth, 
goblet, and intraepithelial cells (30) (31). 
1.1.3 Diagnosis and Treatment 
There are a number of biomarkers [blood c-reactive protein, faecal calprotectin, 
magnetic resonance imaging (MRI), computer tomography (CT) scans and ultrasound 
scans with many more serological and stool biomarkers] are utilised in IBD diagnosis, 
including perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) and anti-
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Saccharomyces cerevisiae antibodies (pASCA), but no single blood test of definite 
diagnostic value exists (32). Abnormalities include anaemia, elevated inflammatory 
markers, electrolyte abnormalities due to diarrhea, vitamin deficiencies as seen in CD 
and low albumin, indicative of both inflammation and poor absorption of nutrients 
(33). Those individuals with severe or complicated disease may require surgical 
intervention (34). 
A wide range of pharmacological agents are currently used in the treatment of IBD 
(35). These include, the mesalamine derivatives (mesalamine, sulfasalazine, 
olsalazine, and balsalazide), glucocorticoids (prednisolone, methylprednisolone, 
hydrocortisone, and budesonide), and immunomodulators (6-mercaptopurine, 
azathioprine, methotrexate, cyclosporine, and tacrolimus) (36). New biologics consist 
of monoclonal antibody therapy – TNF-α inhibitors (infliximab, adalimumab, 
certolizumab, and golimumab), integrin receptor antagonists (vedolizumab and 
natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab) which are 
approved for the use in IBD (36). 
Other novel agents include Janus kinase inhibitors (tofacitinib), antisense 
oligonucleotides (mongersen), sphingosine-1-phosphate (S1P) receptor agonists 
(ozanimod), and anti-integrin inhibitors. Janus kinase inhibitors interfere with the 
signalling pathway that is required for the inflammatory process, whereas the 
antisense oligonucleotides prevent the translation process by binding to mRNA from 
which the protein is usually synthesized. S1P receptor agonists decrease the total 
circulating lymphocyte count, especially CD4+CCR7+ and CD8+CCR7+ T cells (36). 
Other experimental treatments included intravenous immunoglobulins, exclusive 
enteral nutrition and granulocyte colony-stimulating factors. Micro-RNAs have also 
demonstrated their role as disease biomarkers and could become useful for the 
treatment of IBD. Finally, cellular therapy is another therapeutic approach which is 
still under development, but aimed at severe and/or refractory CD (37). 
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The available treatments have several drawbacks, the most important of which is the 
30% primary non-responder rate (38). Some patients transiently show a loss of 
response which are namely, the secondary non-responders (38). Also, the available 
agents are associated with serious adverse effects such as antibody formation, 
malignancies, reactivation of tuberculosis and hepatitis (36). Additionally, two 
chemokine inhibitors have undergone clinical trials to evaluate their efficacy in 
treating IBD, including bertilimumab which is the chemokine CCL11 – inhibitor, 
trialled in both, phase II CD and UC, and E6011 which is a CX3CLI – inhibitor, that is 
used in both phases I and II CD (36).  
1.2 Chemokines CCR6 and CCL20 
Chemokines are a superfamily of immune-modulatory small protein molecules, 
which regulate leukocyte migration to inflammatory sites through their 
chemoattractant properties (39). The total chemokine repertoire consists of 50 
chemokines and they belong to receptor and ligand cohorts (40). Chemokines consists 
of four subgroups named, XC, CX3C, CXC, and CC, in which the naming is based on 
their receptors (41). A receptor is denoted by R, and therefore, Cysteine-Cysteine (C- 
C) chemokines bind with CCR chemokine receptors (42). Chemokines display a 
common molecular structure, having three beta-pleated sheets with an alpha helix at 
the carbon terminal, in which the cysteine motifs are joined by disulphide bonds. The 
entire chemokine is composed of 67–127 amino acid residues (42). Chemokine 
receptors are expressed on the cell surface and they are seven transmembrane, 
guanine nucleotide-linked, G1 class receptors (43). Several chemokine receptors can 
be activated by many ligands,  whereas other receptors are activated by a single ligand 
(44). Chemokines play a prominent role in inflammation and the spreading of cancer 
and chemokine inhibition, has yielded anti-inflammatory attributes in inflammatory 
disorders (45). 
Chemokine receptors are present on a wide range of immune and non-immune cell 
types (46). The C-C motif chemokine ligand 20 (CCL20), the only known monogamous 
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ligand which binds with C-C motif chemokine receptor six (CCR6), has been 
evaluated in this study as an inflammatory biomarker. CCL20 is produced in copious 
amounts by the gut epithelium, in response to infectious microbial penetration that 
attracts the CCR6+ immune cells to the site of infection (47). In spite of the many varied 
biological functions performed by the CCR6-CCL20 axis, one of its primary functions 
is to aid leukocyte homeostasis in the intestines (48). 
Among a plethora of functions, chemotactic navigation of effector T helper cell cohorts 
to the gut mucosa from lymphatics appears to be primarily a CCR6-driven 
mechanism, (where chemotaxis of CCR6+ immune and non-immune cells occur in 
response to CCL20 produced by the gut epithelial cells), which synchronizes immune 
homeostasis during IBD pathophysiology (49). The CCR6–CCL20 axis is a prominent 
immune modulator in both the innate and the adaptive immune responses of a wide 
range of inflammatory diseases (50). It is also associated with tissue damage and 
injury, human immunodeficiency virus (HIV), ophthalmic disorders, lung and kidney 
disorders, autoimmune diseases, brain disease, arthrosclerosis, obesity, diabetes and 
cancer (Figure 2) (42).  
1.2.1 C-C motif Chemokine Receptor 6 (CCR6)  
CCR6 is denoted by a string of different gene codes, (for some which do not have 
expanded names), such as cluster of difference 196 (CD196), CKRL3, G - protein 
coupled receptor 29 (GPR29)-, CKR-L3, CMKBR6, GPRCY4, STRL22, BN-1, DCR2, 
DRY6, CCR-6, and C-C CKR-6. CCR6 is understood to transduce signals that mobilize 
intracellular calcium ion influx upon binding to its ligand, CCL20 (51). CCR6 is a 
commonly expressed molecule on the T lymphocyte subdivisions of TH17 and Treg 
cells, innate lymphoid cells-3 (ILC)-3, neutrophils, natural killer T cells (NKT) cells, 
macrophages, B cells, and immature dendritic cells (52).  
Tissue - specific imprinting of CCR6+ cell types have been identified. Given the 
numerous organ systems in which CCR6 is present and activated, in addition to T 
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helper lymphocytes (TH1, TH2, TH17 and Treg subsets), are alveolar macrophages, 
alveolar epithelial cells, fibroblasts, gamma-delta T cells and dendritic cells (Table 1, 
Figure 2) (42). CCR6 is predominantly expressed in the appendix, pancreas, lymph 
nodes, and spleen, with lesser expression in the foetal liver, testis, colon, small 
intestine, and thymus (53). Distinctively, CCR6 is thought to trigger the 
phosphoinositide - 3 kinase (PI3K) signal transduction cascade, which leads to 
phosphorylation that provides energy for cell chemotaxis (54). This receptor is 
important for B-lineage maturation and antigen-driven B cell differentiation, and it 
may regulate the migration and recruitment of dendritic cells, T and B cells during 
inflammatory and immunological responses (55). Among the ligand independent, 
biological functions of CCR6 are; (i) embryonic development (ii) angiogenesis (iii) 
wound healing (iv) lymph organogenesis and (v) tumour proliferation and metastasis 
(42). 
1.2.2 C-C motif Chemokine Ligand 20 (CCL 20) 
CCL20 was recognized as the principal ligand of CCR6 through calcium ion influx 
experiments in the first human immortalised myelogenous leukemia cell line (K562), 
devoid of other chemokine receptors (CCR1-5), but transfected with CCR6 (53). CCL20 
has synonyms, such as LARC (liver and activation-regulated chemokine), MIP-3α 
(macrophage inflammatory protein), and Exodus-1. Expression of CCL20 is 
upregulated by intestinal enterocytes responsive to bacteria displaying flagellar 
movement, as well as, antigen-presenting dendritic and macrophage subsets, 
Langerhans cells in the skin, endothelial cells, natural killer (NK cells), neutrophils, B 
cells, and TH17 cells (53).  
Apart from CCL20, human beta defensins (HBD), which are a group of microbicidal 
peptides, have been identified as additional epitopes, although this needs thorough 
validation (56). There is increasing evidence that the counterpart of the CCL20 ligand, 
HBD2, concomitantly contributes to epithelial cell migration, in maintaining intestinal 
epithelial barrier integrity, and as such, acts as a frontline defence against microbial 
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invasion (57). Vongsa et al., (2009) reported equipotent functionality of HBD2 to 
CCL20, demonstrating that it stimulates active migration of the human intestinal cell 
lines; human epithelial colorectal adenocarcinoma cell line 2 (Caco2), transplantable 
human carcinoma cell line (T84) and non-transformed intestinal epithelioid cell line 
number six (IEC6), ex vivo. These investigations further confirmed that HBD2 can 
stimulate intracellular calcium influx, which innervates the PI3K signal transduction 
via mobilizing the guanosine triphosphatase (GTPase), Ras homolog family member 
A (RhoA), and phosphorylated myosin light chain, leading to F-actin accumulation,  
which is a possible canonical wound healing mechanism (57). Therefore, HBD is 
thought to augment immune cell patrolling, microbial defence and intestinal barrier 
restitution. These results significantly underpin the notion that HBD2 parallels the 
functions of CCL20 in its role as an additional partnering ligand of CCR6 (44). 
1.2.3 Signalling Pathway Modulated by CCR6-CCL20. 
Chemokines act by binding to specific cell surface receptors that are differentially 
expressed on diverse cell types (58). The receptors are members of a large subfamily 
within the seven-transmembrane domain G - protein coupled receptor superfamily 
(59). At the biochemical level, chemokine receptors act as guanine nucleotide 
exchange factors, restricted mainly to the pertussis–toxin sensitive G1 class of G - 
proteins (60). At the immunological level, they coordinate the development, 
differentiation, anatomical distribution, chemotactic migration and effector 
capabilities of leukocytes (61). 
Cell responses to chemo-attractants typically make them sensitive to pertussis toxin, 
which indicates heterotrimeric G - proteins from the G1 class are coupled to the 
signalling pathway downstream of the receptor as shown in Figure 1 (42). Activated 
G - protein heterotrimers (G-alpha, G-beta, G-gamma), release guanosine di 
phosphate (GDP) and bind guanosine tri phosphate (GTP), which dissociates 
afterwards into G-beta, gamma (Gβγ) subunit complexes and G-alpha (Gα) subunits. 
In leukocytes, Gβγ activates membrane-associated phospholipase C-β2 (PLC) and 
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phosphoinositide 3-kinase (PI3K) (42).  PI3K catalyses phosphatidylinositol 4,5-
bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate (PIP3) which is 
subsequently converted into inositol triphosphate (IP3) and di acyl glycerol (DAG) by 
activated PLC (42). IP3 regulates the mobilization of calcium ions from intracellular 
stores and DAG acts in conjunction with calcium to activate various isoforms of 
protein kinase C (PKC) (42). Activated PKC and various calcium (Ca)–sensitive 
protein kinases catalyse phosphorylation, thereby activating a series of signalling 
events ending up in cell migration (42).  
          
 
 Figure 1. Schematic representation of C-C chemoattractant cytokine (chemokine) 
receptor 6 (CCR6) activation pathway. After binding with the ligand, G - Protein 
Coupled Receptors (GPCR) are activated to release the G-beta (Gβ) and G-gamma 
(Gγ) subunits which in turn activate PLC and PI3K. PI3K then converts PIP2 to PIP3 
which activates calcium ion mobilization across IP3. IP3 with DAG stimulated by 
calcium ions activate PKC and other PKCs which trigger phosphorylation causing cell 
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migration. Legend for abbreviations: G-alpha (Gα), G-beta (Gβ), G-gamma (Gγ) —
Subunits of G-protein coupled receptor (GPCR), PI3K—Phosphoinositide 3 kinase, 
PLC—Phospholipase Cβ2, DAG—diacylglycerol, PIP2—Phosphatidylinositol 4,5-
bisphosphate, PIP3—Phosphatidylinositol 3,4,5-triphosphate, IP3—Inositol 
triphosphate, PKC—Protein kinase C, ER—endoplasmic reticulum, Ca+2—Calcium 
ions. Reproduced from Copyright 2003, CRC Press: Boca Raton, FL, USA. (40). 
CCR6 and CCL20 have exhibited characteristics in line with both immune homeostasis 
and immune activation. It is already established that the immunological impact of this 
chemokine receptor–ligand partnership has far reaching consequences in health and 
disease that affect multiple organs of the human body (42). Several research studies 
have demonstrated that the CCR6-CCL20 axis directly influences the nervous, 
respiratory, gastrointestinal, excretory, skeletal, and reproductive systems via 
pleiotropic immune mechanisms, manifesting as diseases with high mortality rates as 
shown in Table 1 and Figure 2. Given the exclusive roles that CCR6 and CCL20 play 
in clinical pathophysiology, this chemokine pair is considered as a potential 
therapeutic target, whereby the blockade or inhibition of either partner is expected to 
produce successful pharmacotherapy, as a treatment for its related diseases (42). 
Hence the effect of gene ablation of Ccr6 locus on secondary lymphoid organs was 
investigated. No studies have been conducted so far on investigating the impact of 
chronic colitis on other organ systems in Winnie and therefore, spleen, liver and 
kidneys were examined to understand the multi-system pathophysiology arising 
because of IBD. Further, since CCR6 plays a pivotal role in immune cell chemotaxis, 
the upregulation of CCL20, PI3KP and AktP in colon tissue during colitis was also 





Table 1. Organ systems and the diseases in which CCR6/CCL20 axis is operative 
along with the cell types involved in the disease progression which express CCR6. 
Organ CCR6/CCL20 
Axis 





Lung Operative Fibroblasts, AEC, DC, 
TH1, AM 
IPFL, Sarcoidosis (62), 
(63),(39) 
Liver Operative TH17, Treg, (γδ) T cells Chronic liver 
disease 
(64),(64)  
Kidney Operative TH1, TH17, Treg Glomerular 
nephritis 
(65),(66) 
Brain Operative TH1, TH17, (γδ) T cells EAE, Stroke (67)  
Eye Operative TH17 Dry eye disease (68) 
Skin Operative TH17 Psoriasis (69)  
Joints Operative CD25-FoxP3+ Rheumatoid 
arthritis 
(70) 


















Figure 2. Schematic representation of the immunological impact of CCR6/CCL20 
axis on multiple organs in the human body, with the cells involved in promoting 
disease given next to each organ. Experimental Autoimmune Encephalitis (EAE), 
Idiopathic Pulmonary Fibrotic (IPF) lungs, Chronic liver disease, Dry Eye Disease 
(DED), Rheumatoid arthritis, IBD, Psoriasis, Glomerular nephritis, HIV and Cancer 
metastasis are all diseases driven by the CCR6-CCL20 axis and disease progression 
leading to pathogenesis is promoted by T helper lymphocyte subsets, particularly 
TH17 and a decrease in Treg cells. The factors which tilt the TH17-Treg balance, 
influenced by transcription factors and cytokines in the tissue microenvironment are 
yet to be discovered. Legend for abbreviations: Experimental Autoimmune 
Encephalitis (EAE), Idiopathic pulmonary fibrosis (IPF) lungs, Dry Eye Disease 
(DED), IBD, Human Immunodeficiency Virus (HIV), APC—Antigen Presenting Cell, 
MHC Class II—Major Histocompatibility Complex Class II, AM—Alveolar 
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Macrophages, DC—Dendritic Cells, FB—Fibroblasts, AEC—Alveolar Epithelial Cells, 
CCR6—Chemokine receptor 6, CCL20—Chemokine ligand 20, IL—Interleukin, T 
helper lymphocyte 1, 2 and 17 (TH1, TH2, TH17), Treg—Regulatory Treg cells, (γδ) T 
cells—gamma delta T lymphocytes, NF-kB—nuclear factor kappa B, STAT3—signal 
transducer and activator of transcription 3. TNF-α—tumour necrosis factor-alpha. 
(42). 
Sixteen tractable inhibitors of CCR6 and its sole ligand, CCL20 have already been 
identified (Table 50), (Figure 3) and some have even undergone clinical trials for the 
treatment of several autoimmune disorders such as experimental autoimmune 
encephalitis (EAE), rheumatoid arthritis (RA) and psoriasis (73). No such clinical trials 
have been performed with the existing inhibitors to date in IBD, which is also 
considered by some as an autoimmune disease.  
                                    
Figure 3. CCR6–CCL20 axis inhibitors investigated in pre-clinical and clinical 
studies to date as possible therapeutics for autoimmune and inflammatory diseases 
in multiple organ systems: nervous, skeletal, integumentary and gastrointestinal 
systems. CCR6 inhibitors are given above as a cluster, and CCL20 inhibitors are given 
below as a cluster. Legend: MAPK—mitogen activated protein kinase, p—protein, 
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CCL20—CC chemokine ligand 20, mAbs—monoclonal antibodies, CCR6—CC 
chemokine receptor 6, hCCR6—humanised CCR6, Abs—antibodies, IL—interleukin, 
BET—bromodomain extra-terminal proteins, R—receptor, MIR-150—micro 
ribonucleic acid-150, AOP-RANTES—amino oxypentane regulated on activation, 
normal T cell expressed and secreted (73). 
1.3 Role of CCR6-CCL20 in Gut Immune Function  
CCR6 plays an exclusive role in facilitating chronic colitis (42), (53), (74). It makes a 
significant contribution to T cell differentiation and helps to establish the TH1/TH2 
and TH17/Regulatory T cells (Treg) imbalance paradigms in IBD (75). The principal 
mechanisms of adaptive immunity encompass CD4+ T cells and its subsets in 
enforcing immune activation in the gut (76). Naïve TH0 helper cells are transformed 
into effector T helpers upon antigen - sampling by dendritic cells and / or 
macrophages in the mesenteric lymph nodes.  The effector T helpers consist of four 
congenial immune subtypes: TH1, TH2, TH17, and regulatory Treg cells. Thus, recent 
interest has been focused on the two subgroups of TH17 and Treg cells in the immune 
induction of IBD (76).  
These two subgroups of T helper lymphocytes have demonstrated distinctively 
opposing functional roles, primarily attributed to their different cytokine profiles, 
represented by inflammation-triggering - IL-17 and inflammation-dampening - IL-10, 
respectively (40). TH17 induces disease activation by releasing inflammatory 
cytokines leading to tissue damage, while Treg cells promote immune tolerance, 
induced by inflammation-suppressive cytokines which aid tissue restitution (77). The 
underlying mechanisms favouring these two opposing roles are not yet clear, but the 
expression of CCR6 is considered the cardinal determinant in their selective 
proliferation to maintain immune homeostasis (74). Immune homeostasis is 
maintaining the immune responsivity and the ability to overcome disease 
manifestation by sustaining the fine balance between both inflammation and 
resolution. This underpins the concordant, yet enigmatic role that CCR6–CCL20 axis 
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performs in primarily resolving the IBD immune mechanisms, also by promoting 
immune tolerance. Immune tolerance is the ability to suppress disease symptoms and 
defend against all the factors which promoted disease manifestation in the individual. 
The discovery of factors which skew the selection of TH17 and Treg cell polarization 
in the gut mucosa would be a significant breakthrough in IBD therapy (74). 
Multiple cytokines and transcription factors serve to upregulate CCR6 expression on 
the TH17 cells (78). Transforming growth factor-beta sulphate (TGF-β), interleukin 
(IL) - 6, IL-17, IL-21 and IL-23, as well as the lineage-selective master transcription 
factors, retinoic-acid-receptor-related orphan nuclear receptor gamma t (RORγt) and 
retinoic-acid-receptor-related orphan nuclear receptor alpha (RORα), are important 
regulators in upholding the immune induction of CCR6, which is the hallmark of the 
TH17 cell cohort and they are strongly associated with autoimmune diseases (53). IBD 
invariably falls under the direct influence of the pro-inflammatory apparatus driven 
by CCR6, including the TH17 cell differentiation and proliferation (77). Well-
documented studies report that neutralizing IL-17 as well as TH17 cells lacking CCR6 
receptors, serve to markedly inhibit several autoimmune disorders (79).  CCR6 is a 
double-edged sword because of its additional ability to mobilize the immune-
suppressive T cell population consisting, the natural regulatory Treg cells induced by 
the transcription factor FoxP3. The Treg cells are highly effective in modulating 
autoimmune disease progression by actively suppressing pro-inflammatory T cell 
proliferation (80). 
Concomitantly, CCR6 drives chemotactic recruitment of TH17and Treg cell subsets to 
sites of infection in a self-sustained feedback loop, because TH17 cells also could 
express CCL20, induced by the cytokines TGF-β and IL-6 and the transcription factor, 
STAT3 (81). Given the dubious role played by CCR6 in disease amelioration, there 
remain a repertoire of hitherto unidentified factors (82). They are chemokines, 
cytokines, adhesion and costimulatory molecules and a collection of innate immune 
induction factors which are associated with CCR6 immunity and contribute towards 
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the selective mobilization of TH17 cells versus Treg distribution, at the sites of 
inflammation (82). The most recently introduced immunological concepts about IBD 
links the deregulated TH17 and Treg axis as the pivotal point which decides the fate 
of IBD resolution (78). 
Research from different groups have conferred opposing roles to TH17 and regulatory 
Treg cells in inflammatory disease (74). IL-23 - induced TH17 differentiation is known 
to promote inflammation and intriguingly, TH17 cells also release CCL20, the 
chemokine ligand of CCR6. With either an autocrine or paracrine secretion of CCL20, 
TH17 cells also trigger a self-perpetuating cycle at inflammatory locations in a positive 
feedback loop (74). The IL-17 production also induces TNF-α and IL-1β, pointing 
towards an inflammatory pathway involving the nuclear transcription factor, NF-kB 
(74). The FoxP3+ bearing regulatory Treg cells are primarily disease suppressive in 
function and promote disease resolution by downregulating the pro-inflammatory T 
cell proliferation induced by TGF-β and IL-10 production (42). 
CCL20 can be induced in several cell types by lipopolysaccharide (LPS) and  could be 
stimulated and up-regulated by the inflammatory cytokines; interleukin 1 alpha (IL-
1α) and tumour necrosis factor – alpha (TNFα) during acute inflammation (83). CCL20 
expression is constitutively up-regulated by other inflammatory cytokines, namely, 
gamma interferon (IFN-γ), interleukin 1-beta (IL-1β), IL-17, IL-21 (84). In contrast, IL-
10, which is anti-inflammatory, downplay the CCL20 expression which does not  
favour the accumulation of regulatory T cells, particularly at inflammatory locations 
(83). IL-4, IL-22 and surprisingly, IL-23 have reported insignificant stimulatory effects 
on CCL20 expression (83). CCR6 confers an antagonistic function in the TH17 and 
Treg cells, although it is unknown what other factors are responsible for tipping the 
balance in favour of disease progression (40). The CCR6-CCL20 axis remains the 
pivotal point which determines reciprocal generation of these two cell types (TH17 




A disrupted CCR6-CCL20 axis only leads to the development of inflammation 
because CCR6 is adequately expressed on regulatory T cell populations in the cure 
phenotypes (85). A study involving the transfer of “wild type” TH17 cells and CCR6 
- deficient T cells into a “Rag1−/− severe combined immune deficient (SCID) mice” 
resulted in extreme intestinal inflammation and a subsequent reduction in TH17 and 
Treg populations occurring (85). CCR6 expression is deemed to be critical to Treg cells 
than to TH17 cells, because this subset suppresses pro-inflammatory T cell 
proliferation and promotes disease resolution (86). However, research documented so 
far has failed to identify the exact role played by CCR6 in inflammation and immune 
homeostasis (86). 
1.3.1 Immunologic Pathways Linking CCR6-CCL20 Axis to IBD 
Pathogenesis 
A person afflicted with one immune-mediated affliction, will also run a high risk of 
contracting another disease of the same type (87). This overlapping aetiology is 
attributed to common clinical and immunological parameters concomitantly shared 
by those disorders (87). It led us to a systematized examination of the various immune-
activation pathways involving the chemokine receptor 6, as shown in Figure 4 as well 
as Table 2 that culminate in immune-mediated disease pathogenicity in IBD (53). 
Table 2. Different CCR6-driven immune pathways, their mechanisms, and disease 
outcomes. 
 
Pathway Link to CCR6 Mechanism Outcome Ref 
TH1/TH2 CCR6+ TH1 cells 
Migration of CCR6+ TH1 cells 
to the intestine, attracted by 
CCL20 produced by the IEC 
and their release of 
proinflammatory cytokines 





TH1/TH17 CCR6+ TH17 cells 
Induced by IL-23, RORγt, and 
TGF-β, TH17 cells, upon 
differentiation, release IL-17A–
F, which drives CCR6+ TH17 
cell recruitment towards the 
intestinal epithelium, attracted 





TH17/Treg CCR6+ Treg cells 
Induced by TGF-β and FoxP3, 
regulatory Treg cells, after 
differentiation, release IL-10, 
which drives CCR6+ Treg cells 
towards the intestinal 
epithelium, attracted by 







IL-12, STAT3, and IL-23-
induced CCR6+ TH17 cells 
migrate towards the intestinal 
epithelium, stimulated by IL-
17A–F and attracted by CCL20 







CCL20 activates Akt/ERK-1/2 
and SAPK/JNK MAP kinases 
to increase cell proliferation 
and cell mobilization in the 
intestinal epithelium. 
Homeostasis (93) 
ILC CCR6+ NCR+ ILC3 
Induced by IL-22, 
CCR6+ NCR+ ILC3 release IL-
12 and activate IFN-γ-





IL-23-producing ILC1 activate 
NCR+ ILC3 to express MHC 
class II epitopes to initiate 
transformation of naïve T 




Induced by IL-22, CCR6+ ILC3 
migrate to Peyer’s patches, 
attracted by CCL20 produced 





Figure 4. Schematic representation of the CCR6-involving immune pathways in 
IBD in the gut mucosa and priming of naïve CD4 T cells into effectors in mesenteric 
lymph nodes with their associated cytokines. Legend: APC—Antigen Presenting 
Cell; TH—T helper lymphocyte; M—Microfold Cell; Treg—Regulatory Treg Cell; 
ILC3—Innate Lymphoid Cell 3; MHC Class II—Major Histocompatibility Complex 
Class II; γδ T—Gamma delta T Cell. (53). 
 
 
results in loss of immune 
tolerance. 
TH9/TH2 CCR6+ TH9 cells 
Induced by retinoic acid, TGF-
β and IL-10 released by ILC3 
effect differentiation of 





Induction by IL-9 elicits 
antiparasitic or allergic 





1.3.2 Specific Pathological Changes Caused by CCR6-Deficiency in 
Colitis 
The small intestine is the primary site of inflammation as it is exposed to a significant 
load of bacterial antigens and nutrients (42). It is covered by a single layer of 
epithelium, containing epithelial cells, Paneth cells, entero-endocrine cells, microfold 
(M) cells, and mucous-secreting goblet cells (98). Most of the immune action takes 
place in Peyer’s patches, where the follicle-associated epithelium (FAE) is crossed by 
antigen samplers, which stimulate naïve T and B cells to develop into effectors (98). 
Effector T and B lymphocytes are always found patrolling the mucosal surfaces in the 
gut during inflammation which helps the intestinal mucosa to maintain a healthy 
protective immune response to the numerous colonies of symbiotic microbes present 
within the gut (99).  
Gut tolerance mainly occurs in Peyer’s patches and isolated lymphoid follicles (40). 
Antigen uptake in the gut-associated lymphoid tissue (GALT) mostly occurs via M 
cells in the FAE in Peyer’s patches by dendritic cells (100). The CCR6-bearing dendritic 
cells are attracted towards CCL20-producing epithelial cells and thus migrate towards 
the mucosa-associated connective tissue, the lamina propria (LP), to activate naïve T 
and B lymphocytes (101). Primed effector cells drain out of afferent lymphatics to the 
mesenteric lymph nodes, from where they enter the thoracic duct and then join the 
bloodstream and return through the network of vessels back to the intestinal mucosa 
(102). The activated T helper cells stimulate naïve B cells into antibody-producing 
plasma cells. The antigen-primed B lymphocytes are transformed into class-switching 
B plasma cells that secrete IgA in the gut mucosa upon antigen presentation and 
activation by dendritic cells (103). 
The CCR6-deficient models have displayed an overall change in the architecture of 
the intestinal epithelium, with smaller Peyer’s patches, a lesser number of 
subepithelial domes, absence of isolated lymphoid follicles, few intestinal M cells, and 
high resistance to bacteria which enter through M cell conduits (104). Other significant 
21 
 
IBD-relevant responses included, marked elevation in the number of TH17 cells in the 
spleen and lymph nodes, low preference for migration to inflamed sites, and less 
suppressive capabilities of Treg cells (74). The other evidence included [Dextran 
Sodium Sulphate (DSS) - and Trinitrobenzene Sulphonic Acid (TNBS)] - induced 
colitis producing moderate and severe disease, respectively, in CCR6-deficient mouse 
models and the reconstitution of Rag2−/− SCID mice with naïve T cells from healthy 
mice resulting in acute inflammation (105). 
Typical histological changes induced by DSS in mouse models include; mucin and 
goblet cell depletion, epithelial erosion and ulceration (106). Further, DSS induced an 
influx of neutrophils into the lamina propria and submucosa. Chronic DSS colitis 
resulted in mononuclear leukocyte infiltration, crypt architecture disarray and a 
widening of the gap between the base of the crypt and muscularis with deep mucosal 
lymphocytosis (106). DSS-treated CCR6 knockout mice had remarkably reduced 
intestinal pathology (shortening of the long axis of intestine, thickening of intestinal 
wall) particularly as they showed recovery in between DSS-free periods (106). They 
also showed accumulation of TCRαβ cells in the gut mucosa with a significant 
elevation of mRNA by many folds in CD8+ T cells compared to CD4+ at the beginning 
of DSS treatment (106). Interestingly, in DSS-treated CCR6−/− mice, there was no major 
difference in these T cell populations during the acute phase of colitis although in the 
WT the numbers decreased drastically. It points to CCR6 being needed for trafficking 
and limiting T cell populations into the intestinal mucosa during acute IBD. It is 
widely accepted that CCR6 plays a key role in the mobilization of T lymphocytes, 
highlighting the mobilization of pro-inflammatory cell types in the intestines. The 
accumulation of TCRαβ lymphocytes in the gut during colitis reported by Varona et 
al., further supports this observation. However, WT mice otherwise resistant to TNBS 
- induced colitis became more susceptible to TNBS when CCR6 was deleted (106). 
Mouse models of acute colonic inflammation, however, are conflicting in their results. 
In the TNBS model of colitis, CCR6−/− mice developed severe colitis compared to WT 
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mice (40). In a third widely used classical model of colitis induced by T cell transfer, 
naïve T cells from CCR6−/− mice transferred into Rag2−/−mice caused a very severe 
colitis compared to CCR6+/+ transferred T cells (40). In this model, CCR6−/− T reg cells 
displayed less suppressive capabilities and reduced migration to the site of 
inflammation compared to WT Treg cells. This indicates that the protection from 
colitis is offered by a novel colon-homing, IL-10-producing CCR6+ regulatory T cell 
population (40). Using a T cell-depletion model of colitis, it was demonstrated that 
TH17 cells accumulated in great numbers in the small intestine when a strong T cell 
receptor stimulus was present. More importantly, it was established that this TH17 
accumulation was dependent on the CCL20-CCR6 axis and that these TH17 cells, 
interestingly, acquired an immunosuppressive phenotype in the gut, rather than the 
typical inflammatory phenotype associated with this cell subset (40). This was 
determined when the accumulated TH17 cells were able to suppress 
carboxyfluorescein succinimidyl ester (CFSE) - labelled responder T cells (CD4+CD25−) 
in an in vitro suppression assay and prevented the establishment of EAE in 
experimental transfer models (in vivo). The likely mechanism of these cells is through 
the secretion of the immunosuppressive cytokine IL-10 (40). 
Chemokine-directed migration of leukocyte subsets are thought to contribute to the 
qualitative differences between systemic and mucosal immunity (40). An early study 
had demonstrated that in mice lacking CCR6, dendritic cells expressing CD11c and 
CD11b were absent from the subepithelial dome of Peyer's patches (49). These mice 
also had an impaired humoral immune response to orally administered antigen and 
to the enteropathy rotavirus (49). In addition, CCR6 (-/-) mice have a 2-fold to 15-fold 
increase in cells of certain selected T lymphocyte populations within the mucosa (49). 
By contrast, systemic immune responses to subcutaneous antigens in CCR6 (-/-) mice 
were normal. These findings demonstrate that CCR6 is a mucosa-specific regulator of 
humoral immunity and lymphocyte homeostasis in the intestinal mucosa (49). 
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 1.4 Importance of Winnie as an Experimental Mouse Model 
Around sixty six different animal models classified under different approaches have 
been used to date, to analyse and understand the complex mechanisms which cause 
pathogenesis in IBD as well as develop novel therapeutic regimes (107). Most of the 
IBD mouse models are genetically engineered to carry a deletion (Knockout – KO) or 
a mutation in the gene of interest (Knock in – KI) and are useful for investigating a 
targeted mechanism. However, most of their inflammatory phenotype had been 
generated either through single mutations, immunologic manipulations or with 
exposure to noxious substances which is not the case in humans where multiple 
genetic, microbial and environmental factors come into play. Therefore, there is a need 
for spontaneous animal models that resemble the multifactorial nature of the human 
disease (108). 
Winnie mice display immune responses through a threefold increase of immune cells 
in the colon compared to WT mice, with a significant increase in mucosal cytokine 
secretion in the gut and produced disease like that of human UC (109). By crossing 
Winnie mice heterozygous for Muc2 (m/+) and Ccr6 (CCR6+/-), we have induced a 
mild, chronic colitis, which strongly resembled human UC in Winnie x Ccr6-/-, which 
was also homozygous recessive for Muc2 and Ccr6 (Figure 5).  To begin with, we 
mated male Winnie m/m with Ccr6 -/- Winnie females, to produce offspring having 
the genotype Winnie m/+ Ccr6 +/- (which is heterozygous for Winnie and 
heterozygous for Ccr6). From mating these heterozygous Winnie mice, we obtained 
mice having the Winnie m/+ Ccr6 -/- genotype. We then mated male Winnie m/+ Ccr6 
-/- with female Winnie m/+ Ccr6 -/- which produced, Winnie m/m, Ccr6 -/- mice.  
Thereafter the male Winnie m/m, Ccr6 -/-   were mated with female Winnie m/m Ccr6 
-/-, which produced Winnie m/m, Ccr6 -/-, which is the experimental model, the 
double homozygous recessive (Winnie x Ccr6-/-). 
Chronic colitis in Winnie is caused by a primary epithelial cell defect that is activated 
by a (point) missense mutation in the Muc2 gene, which resulted in aberrant mucin-2 
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biosynthesis (110). This has led to endoplasmic reticulum stress in the intestinal goblet 
cells which had produced, a decrease in the  secretion of mucus (111). Winnie mice 
display symptoms of diarrhoea, ulcerations, rectal bleeding and pain at different 
stages of colitis synonymous with human disease (112). Exhaustive studies conducted 
in Winnie have proven it to be the best available murine model to study human 
chronic colitis and its pathogenesis (111).  
Winnie, our model of spontaneous colitis, produces chronic intestinal inflammation 
caused by endoplasmic reticulum (ER) stress evident by the reduced number of goblet 
cells, a depleted mucous layer, increased crypt proliferation and apoptosis (110). 
Intestinal permeability is thus increased, by enhanced susceptibility to luminal 
inflammation-inducing toxins (110). Disease severity increases with age and is more 
pronounced in the proximal colon, accompanied by activation of TH1 and TH2 
cytokines, IFN-γ, TNF-α and IL-13 (109).  
Winnie displays both innate and adaptive immune responses, with a threefold 
increase of colonic lamina propria mononuclear cells: CD4, CD8, T cells, B cells and 
CD11b and CD11c, compared to WT mice and also showed a significant increase in 
the mucosal cytokine secretion: IL-1β, IL-12/23 p40 and IL-17 (110).  Winnie also 
provides evidence of the immune deviation from TH1/TH2 control towards enhanced 
IL23/Th17 by expressing increased mRNA for the TH17 signature genes: Il-17a, Il-17f, 
tgfβ and Ccr6 (110). However, skewing the immune response towards IL-23/TH17 is a 
recently emerged pathway in IBD with the concordant contribution of  TH17 cells to 
enhance inflammation and produce disease like human UC (113).  This study has 
therefore become highly clinically relevant in most aspects. 
In summary, the typical functions of the chemokine receptor CCR6 include immune 
regulation by manoeuvring cell chemotaxis and selective delimiting of the pro-
inflammatory TH17 and regulatory Treg subsets during chronic or acute systemic 
inflammation (73). Inhibition of CCR6 is proposed to attenuate disease symptoms and 
promote recuperation of multiple inflammatory and autoimmune disorders (73). The 
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development of Ccr6-inhibition therapeutics is still at an early experimental stage and 
has mostly involved the utilization of pre-clinical models and neutralizing mono or 
polyclonal antibodies against either partner (CCR6 or CCL20) (73). Other methods 
include the constitutive use of small molecules as peptide inhibitors or small 
interfering ribonucleic acid (siRNA) to interfere with transcription at the nuclear level 
(114). A multitude of antibody preparations are already available in the current 
pharmaceutical market as patented treatments for diseases in which the CCR6–CCL20 
axis is operative, yet they must be used only as supplements with existing routinely 
prescribed medication as they collectively produce adverse side effects (115). Novel 
inhibitors are needed to evaluate this invaluable therapeutic target which holds much 
promise in the research and development of appropriate remedies for inflammatory 
diseases.  
CCR6, is a chemokine receptor that is abundantly expressed by a variety of immune 
and non-immune cells (39). CCR6 binds CCL20, although members of the β defensin 
family also bind CCR6 with a lower affinity (57). In addition to the gut, CCR6 positive 
cells, and the chemokines, CCR6 and CCL20, have been detected in numerous organs, 
especially the secondary lymphoid organs (42). CCL20 is selectively made by the 
follicle-associated epithelium (FAE) overlying Peyer’s Patches (PPs) and isolated 
lymphoid follicles (ILFs) (47). CCL20 contributes to the recruitment of CCR6-
expressing cells to these structures (47). In humans, CCR6 and/or CCL20 have been 
implicated in the pathogenesis of inflammatory bowel disease and a wide spectrum 
of disorders involving many organ systems (42). It suggests that CCL20 and CCR6 
have a role in inflammatory diseases, by recruiting TH1, TH2, TH17 and Treg cells to 





1.5 The Reasons for Undertaking this Study 
1.5.1 Aims of this Study 
Aim 1: Understand the functional role of Ccr6 in spontaneous IBD by assessing its 
impact on multi system pathophysiology. 
Aim 2: Understand the functional role of Ccr6 in the immunology of spontaneous IBD. 
Aim 3: Understand the functional role of Ccr6 in relation to molecular signalling in 
spontaneous IBD.   
1.5.2 Rationale of this Study 
The impact of CCR6 in IBD has not been comprehensively studied and its exact 
immunological behaviour has not been elucidated. Therefore, we have investigated 
the effect of Ccr6 gene ablation in a model of spontaneous colitis to evaluate the 
murine immune profile, which will indicate: (i) reduced leukocyte migration to 
inflammatory locations and hence, (ii) reduced release of pro-inflammatory mediators 
at the sites of inflammation, which is expected to produce (iii) reduced mucosal 
inflammation leading to subsequent disease amelioration. CCR6 plays an exclusive 
role in facilitating chronic colitis (111). It makes a significant contribution to T cell 
differentiation and helps to establish TH1/TH2 and TH17/Treg cell imbalance 
paradigms (111). 
1.5.3 Hypothesis 
The central hypothesis of this study was that the loss of CCR6 will ameliorate 
inflammation in the murine model of spontaneous colitis, Winnie x Ccr6-/-.  This study 
was conducted to investigate the therapeutic potential of CCR6 in this model, where 
our results showed a considerable reduction in colitis. 
The usefulness of this study is threefold; as the Winnie mouse model is a spontaneous 
colitis model which mimics human UC, the genetic deletion of Ccr6 is expected to 
27 
 
ameliorate disease symptoms by reducing inflammation in the colon. Hence, CCR6 
provides us with a possible manipulative therapeutic target in IBD.   
1.5.4 Anticipated Benefits 
The anticipated benefits of this study are the existing compelling evidence that CCR6 
has multiple immune functions in many organ systems of humans and is considered 
a valuable therapeutic target (Figure 2, 3) (42) (73). From preclinical studies, it is hoped 
that the immune cell triggers or pathways that arise from CCR6 activation could be 
identified (53). These results could then be translated into clinical trials which target 
the neutralization of CCR6 or its associated cytokines/ products /mediators in human 
colitis.    
Winnie, a tested and proven model of murine spontaneous colitis which closely 
resembles human UC, was used in which the Ccr6 gene was knocked out. We 
determined clinical, histological and immunological parameters at two timepoints (8 
weeks of age and between 16-22 weeks of age), which delineates the impact of CCR6 
- deficiency in terms of its potential to become a proactive drug target.  
Additionally, we have investigated the sequel of CCR6 deficiency in multi-system 
pathophysiology with the spleen, liver and kidneys, to identify a link between the gut 
and other organs which may become inflamed due to microbial dysbiosis that most 
commonly, stems within the enteric system. We have also quantified the percentage 
expression of three biomolecules (CCL20, phosphorylated PI3K and phosphorylated 
Akt) which are downstream targets in the CCR6-related immune signalling pathways 
(116). These preliminary findings are expected to open avenues to a more detailed 
examination of CCR6 immunobiology and physiology in order to evaluate the impact 
of CCR6 inhibition as a treatment option for IBD.    
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2.0 Materials and Methods  
2.1 Experimental Mice  
The mice used in this research project were imported from the Jackson Immuno 
Research Laboratories, Inc. PA, USA and obtained through the Animal Resource 
Centre (ARC) and bred directly at the Cambridge Farm Facility (CFF) of the University 
of Tasmania (UTAS). The mice were re-derived and bred at a specific pathogen-free 
facility at the CFF and transported to the Menzies Institute for Medical Research, 
Hobart, affiliated to UTAS which has a PC2 animal facility. Mice utilised were all aged 
between 8- 22 weeks and were genotyped by the Transnetyx, Automated Genotyping 
PCR services (www.transnetyx.com). The experimental mice genotypes are listed in 
Table 3. All animal procedures were approved by the Animal Ethics Committee of the 
University of Tasmania (Ethics Permit A 17451) and were conducted in accordance 
with the Australian code for the care and use of animals for scientific purposes 8th 
edition of 2013 guidelines set out by the National Health and Medical Research 
Council of Australia.  
The breeding strategy was begun with two main mouse groups, namely, the Winnie 
mouse group and the CCR6 mice group. They were bred and maintained on a 
C57BL/6J background.  C57BL/6J is a mouse strain and both the Winnie mice and the 
CCR6 mice were bred up to ten generations on this parental strain to eliminate genetic 
drift, before our experiments started.  
C57BL/6J-derived Winnie, homozygous recessive for Muc2 indicated by (m/m) but 
homozygous dominant for CCR6 indicated by (Ccr6+/+ )  was crossed with C57BL/6J-
derived CCR6 mice,  homozygous recessive for CCR6 (Ccr6-/-) but homozygous 
dominant for Winnie (+/+), produced Winnie heterozygous (het) mice, which were 
(m/+) (Ccr6+/-), then crossed to obtain Winnie (m/m, Ccr6-/- ) males and females from 




However, the mice utilised in this study were obtained from several litters although 
some mice in each of the four groups were littermates. The reason is, that from mating 
a breeding pair, most often the offspring produced are few in number such as 5-6 
pups, which do not suffice for this research study. Therefore, we had to include mice 
produced from other similar breeding pairs as well. Since these mice were housed in 
the same aseptic environment and were fed with the same diet, we did not expect 
them to carry vastly different colonies of microbiota in their gut. Another fact which 
is worth mentioning is that when the parents of the experimental model are crossed, 
the chance of getting this genotype is rare.  
 
 






Table 3. The mice genotypes utilised with a description of the phenotype, numbers 
culled and their role in the research project. Tissues were harvested for analysis at 
8 weeks and 16-22 weeks of age, respectively.  
Mice genotype 
(Winnie / Ccr6) 




















Muc2 mutation 16 










2.2 Data Collection  
The phenotype was assessed using pre-clinical parameters of each group of mice. The 
body weight was recorded prior to culling and after comparing the mouse number 
and the ear-clip description. The mice were culled using carbon dioxide euthanasia 
for 6 minutes at 0.4 foot-pound (foot-lb).  Having determined the mouse was dead by 
testing for corneal reflex, tail and toe pinch and rolling reflexes, the mice were 
dissected under sterile conditions. The spleen, kidneys and liver were harvested and 
weight of each was recorded. Both the kidneys were weighed together. Spleen was 
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stored in 10 mL of ice-cold phosphate buffered saline (PBS; pH 7.4- Dulbecco’s, 10 x 
L, Gibco, Life Technologies Pty Ltd, Victoria, Australia) on ice for 2 hours after which 
it was processed for analysis by flow cytometry. Spleen, liver and kidneys were stored 
in 10% neutral buffered formalin and transferred into 70% ethanol after 48 hours. 
Mesenteric lymph nodes were harvested and stored in ice-cold RPMI 1640 culture 
medium (Life Technologies Pty Ltd, Victoria, Australia). The large intestine was 
separated at the ileo-caecal junction and the anus and placed on a non-absorbent 
surface. The length of the colon was measured from the caeco-colic junction to the 
anus and was recorded. The whole colon was cut open along the longitudinal axis, 
faecal matter removed, and weight was recorded. One half of the colon cut length wise 
was rolled around a sterile toothpick from the proximal colon to the distal colon end 
and made into a Swiss roll, fixed to a small piece of regiform and preserved in 40 mL 
of 10% neutral buffered formalin. It was transferred into 70% ethanol after 3 days. The 
other half of the colon was cut in the middle into proximal and distal colon and each 
was cut into half again. Pieces of fresh colon tissue were immediately frozen in a 
DNase and RNase-free Eppendorf tube at minus 20 degrees centigrade and later 
transferred to minus 80 degrees centigrade for RNA extraction for analysis by real-
time polymerase chain reaction (RT-PCR).                                  
2.3 Flow cytometry 
Mouse spleen and MLN were macerated using the end of a 10cc syringe plunger with 
ice-cold PBS and passed through a 70 µ corning cell strainer (Catalogue No.  08-771-2, 
Thermo Fisher Scientific Pty Ltd, Victoria, Australia) to prepare a homogenous 
suspension of 20 mL which was centrifuged at 500g for 10 minutes at 4°C (Allegra 
X15R Beckman Coulter, USA) to obtain a cell pellet. The red blood cells (RBC) were 
removed from splenocyte suspensions by adding 1 mL of x 1 RBC lysis buffer 
(Catalogue No. 420301, Australian Biosearch Pty Ltd, Wangarra, WA, Australia) for 2 
minutes at 25°C in the dark, after discarding the supernatant. Ice-cold PBS was added 
up to 25 mL to inactivate the RBC lysis buffer and centrifuged at 500g for 7 minutes at 
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4°C. 10 mL of FACS buffer (Table 4) was added to the RBC-free splenocyte samples, 
vortexed to mix and kept on ice. 10 µl of the suspension was mixed with 10 µl of 
trypan blue and the number of cells were enumerated using a haemocytometer taking 
the average cell count by counting the cells in the 4 corners and centre squares of the 
grid. Around 2 x107 cells per mL was adjusted by adding FACS buffer. 1 mL of this 
prepared sample was centrifuged at 500g for 7 minutes in a microcentrifuge to obtain 
a cell pellet. The supernatant was discarded and 40 µl of fluorescent conjugated 
antibody (Table 5) was added and vortexed briefly to mix and incubated on ice in the 
dark for 30 minutes. The cells were washed in 0.5 mL of PBS at 500g for 7 minutes. 
The supernatant was discarded and 300 µl of FACS buffer was added, vortexed and 
flow cytometric data was obtained using a BD FACS CANTOTM flow cytometer (BD 
Biosciences, USA) and analysed using FCS Express version 6.06.0014 (De Novo 
Software, USA) for windows. Mesenteric lymph node suspensions were processed in 
the same way, without the addition of RBC lysis buffer.  
 
Table 4. Composition of FACS Buffer used in flow cytometry assays. 
 1000 mL PBS X1 
FACS Buffer 10% BSA 












Table 5. List of flow cytometry antibodies used. 

















152408 PE 1:200 
Live/Dead 
Cell Stain 
Invitrogen L-34975 IR 633-635 1:50 
 
2.4 Real Time Polymerase Chain Reaction (RT-PCR) 
2.4.1 RNA Extraction 
Colon tissue less than 30 mg in weight was crushed and homogenized using a plastic 
disposable tip and RNA was extracted using Qiagen RNeasy mini kit (50) (Catalogue 
No. 74104) following the manufacturer’s protocol. 100 µl of RNA was eluted using a 
spin column and purity of eluted RNA was determined using the ratio of absorbance 
at 260nm/280nm using an Eppendorf Bio Photometer (Eppendorf). Samples above 2 
were utilised for RT-PCR.  
2.4.2 Complementary DNA (cDNA) synthesis from RNA 
Complementary DNA (cDNA) was synthesized from RNA samples using a High 
Capacity cDNA Reverse Transcription Kit (Catalogue No. 4368814, Thermo Fisher 
Scientific Australia Pty Ltd, Victoria, Australia) using the reaction conditions (Table 6 
and 7) suggested by the manufacturer. 100 ng of cDNA from each sample was added 
to a PCR reaction including TaqMan Fast Master Mix (Catalogue No. 4444557, Thermo 
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Fisher Scientific Australia Pty Ltd, Victoria, Australia) and a single gene-specific 
primer set supplied in the kit.  
Table 6. Recipe for the cDNA Master Mix and per reaction. 
Ingredients Volume /Reaction (µl) 
10X RT Buffer  2.0 
25X dNTP Mix (100mM)  0.8 
10X RT Random Primers  2.0 
Multiscribe Reverse Transcriptase  1.0 
Nuclease free water  4.2 
Final Volume 10.0 
Volume of cDNA Master Mix per reaction  5.0 
Volume of RNA   5.0 
Final volume per reaction 10.0 
 
Table 7. Thermal cycling conditions for synthesizing cDNA. 




4 Infinite Hold 






2.4.3 The PCR Assay 
Fast SYBRTM Green Master Mix (Catalogue No. 4385612 – Thermo Fisher Scientific Pty 
Ltd, Victoria, Australia) was used with the cDNA template, forward and reverse DNA 
primers in a reaction volume of 20 µl, in pre-determined volumes as per 
manufacturer’s protocol (Table 8). The PCR plate was run (Table 9) on Applied 
Biosystems StepOnePlus TM Real-Time PCR systems (version 2.2.3). The samples were 
run in duplicate and an average CT (Cycle Threshold) value was calculated. The CT 
value for the housekeeping gene Gapdh was subtracted from the CT value of the gene 
under investigation. Gene expression was quantified using the comparative (ΔΔCT) 
method where the threshold cycle (CT) for each gene was normalised to reference 
gene Gapdh. Relative gene expression in the animals was presented as 2−ΔCT. 
Table 8. Recipe for the PCR Reaction Mix. 
Ingredient Volume (µl) x1 
SYBR Green Master Mix 10 
Forward Primer (25ng/reaction)   2 
Reverse Primer (25 ng/reaction)   2 
cDNA template (10-20 ng/reaction)   4 
RNase-free water   2 
Total reaction  20 
Table 9. Thermal Cycling Conditions for PCR. 
Temperature (°C) Duration (sec) 
95 Hold 20 sec 
95 Denature                                             x40 03 sec 
60 Extension                                            x40 30 sec 




Colon tissue which was cut into one half along the longitudinal axis was rolled around 
a sterile toothpick into a Swiss roll, and spleen, liver and both kidneys were placed in 
50 mL of 10% neutral buffered formalin for fixation for 2-3 days. The tissue was then 
transferred into 70% ethanol until chemical processing and embedded in paraffin and 
sections cut to a thickness of 5 µm by a rotary microtome and were stained with Gill’s 
haematoxylin and eosin (H&E). The H&E stained sections were imaged using an 
Olympus DP72 microscope. The tissue sections of colon, spleen, liver and kidneys, 
from all animals were scored in a blinded manner after grading for colitis (Table 20, 
22, 24 and 26) by the histopathologist involved in this study at the Launceston General 
Hospital. Cell counting was performed manually in 10 random microscopic fields at 
magnifications of x100 and x200.  
2.6 Immunohistochemistry 
Colon tissue sections were fixed in 10% neutral buffered formalin for 2-3 days and 
transferred to 70% ethanol, processed, embedded in paraffin, and 5 µm thick sections 
were cut using a microtome. Wax tissue sections were marked using a silicon pencil 
and left in an oven at 60°C for 10 minutes and the dewaxing process begun. The tissue 
was processed for 2 minutes in xylene, rehydrated in a series of ethanol from 100%, 
100%, 95%, 95%, 70%, 70% after which two washes performed in distilled water. 
Antigen retrieval was carried out in 0.1M citrate buffer (pH 6.0) (Table 10) at 
maximum pressure for 6 minutes using a decloaking chamber, allowed to cool under 
running water and rinsed twice in distilled water. 1:10 hydrogen peroxide incubation 
was performed for 10 minutes followed by protein blocking for 30 minutes using the 
Rabbit specific HRP/DAB (ABC) detection IHC kit (Catalogue No. 64261, Abcam, UK) 
following the manufacturer’s protocol. Slides were washed under running water for 
5 minutes and rinsed twice in PBS (Dulbecco’s, Invitrogen, Australia) after each 
treatment. 200 µl of primary antibody (Table 11) diluted 1:100 in supplied antibody 
diluting solution was added and incubated for 1 hour in the dark inside a humidified 
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chamber at room temperature. Rinsed in PBS 3 times and 3 drops of the secondary 
antibody added and incubated for 30 minutes at room temperature.  After rinsing 3 
times in PBS, DAB chromogen + substrate buffer (1 drop of DAB chromogen diluted 
in 1 mL substrate buffer) was added to the tissue sections for 10 minutes and washed 
under running water for 5 minutes, and counterstained with strong liquid Mayer’s 
haematoxylin for 30 seconds, dipped in ammonia water for 1-2 minutes and 
dehydrated in ethanol (70%, 70%, 95%, 95%, 100%, 100%, xylene, xylene), after which 
a mounting medium was added and a coverslip placed on top. 
Table 10. Composition of Citrate Buffer. 
 3.5 mL 0.1M Sodium Citrate 
Citrate Buffer 46.5 mL Citric Acid 
 Up to 100 mL Distilled Water 
 pH adjusted with 0.1M NaOH 
 




CCL20 9829 Abcam, UK 1:200 
PI3KP 78429 Abcam, UK 1:200 
AktP 227100 Abcam, UK 1:500 
 
2.7 Alcian Blue staining of mucus producing goblet cells 
Slides were deparaffinized and rehydrated in a series of alcohol. Stained with Alcian 
blue pH 2.5 for 30 minutes, washed in running water for 2 minutes, rinsed in distilled 
water, counterstained with safranin for 1 hour, washed and dehydrated in alcohol, 
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cleared in xylene and mounted. Acid mucins were stained blue and the nuclei were 
stained in pink (Figure 14).  
2.8 Statistical Data Analysis 
The data were analysed using Graph Pad Prism version 8.4.2 (Graph Pad Software 
Inc., USA). All data were expressed as mean + standard error of mean (SEM) and the 
data were evaluated by one - way analysis of variance (ANOVA) and Tukey’s multiple 
comparison test to compare the mean values between groups. The data was 
considered significant when p < 0.05.  
3.0 Results 
3.1 A Brief Overview of the Genotypes 
This study involved a preliminary investigation of multi-system pathophysiology 
produced by CCR6-deficiency in a novel murine model of colitis with the view to 
phenotype and evaluate its potential to ameliorate UC. Table 12 describes the different 
groups of mice utilised in this study and the reasons for selecting these groups and 
why they were compared. 
Table 12: The investigated genotypes and their ensuing phenotypes.  
Model Genotype 
Winnie / Ccr6 
Description 
C57BL/6J (WT) +/+, +/+ Normal for mucin 2 and normal for CCR6 
Ccr6 -/- +/+, -/- Normal for mucin 2 but no CCR6 
Winnie m/m, +/+ No mucin 2 but normal for CCR6 
Winnie x Ccr6-/- m/m, -/- No mucin 2 nor CCR6 
 
The reasons for selecting the C57BL/6J as the WT was because it is a healthy control 
which had no mutations as well as did not develop the disease. We have compared 
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the WT against Winnie, which carried a mutation in Muc2 gene and hence developed 
colitis. It is already established that the defect in Muc2 produces colitis (111). By doing 
so, we were directly comparing the healthy control with the diseased phenotype, 
using mice generated from the same background strain. Between these two groups, 
we hypothesised that the CCR6 chemokine receptor-ligand activity remained the 
same but produced different outcomes. The Ccr6-/- mice were used to demonstrate 
the influence of the CCR6 receptor activity by comparing the healthy WT control with 
the loss of chemokine CCR6 activity in the WT. We induced the Muc2 mutation in 
Winnie x Ccr6-/- mice (the experimental model) to produce spontaneous colitis in 
these mice and knocked out the Ccr6 gene to investigate the clinical and 
immunological effects arising from the loss of CCR6 activity in the colitis model, 
which was Winnie. Since it is also known that the chemokine receptor CCR6 
upregulates certain autoimmune diseases (42) as well as certain CCR6-inhibitors  had 
produced attenuation of several autoimmune diseases (73), we hypothesised that the 
absence of CCR6 in a colitis mouse model would also contribute towards attenuating 
the disease. A comparison of Winnie x Ccr6-/- and Ccr6-/- was made to see whether 
the loss of CCR6 activity in the WT and Winnie mice were similar or were vastly 
different. Since the WT and Winnie were generated from the same background strain, 
the comparison was deemed to be valid. 
3.1.1 C57BL/6J control mice [WT (Winnie +/+, Ccr6+/+)] 
These mice were purchased from the Jackson Laboratories in the USA and obtained 
via the Animal Resource Centre (ARC). The colony is refreshed every 10 generations 
to prevent genetic drift. It is a tolerant background for the expression of many 
mutations. The C57BL/6J has no gene manipulations. Therefore, with regards to the 
genotype concerning Muc2 and Ccr6 loci, they are homozygous dominant and could 
be described as +/+ for Winnie which means the dominant form of m/m and +/+ for 
Ccr6. It means that these mice are healthy and have normal mucin production and as 
a result, do not develop the disease although they carry the CCR6 chemokine receptor.  
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3.1.2 Winnie mice (m/m, Ccr6+/+) 
These mice are on the C57BL/6J parental background carrying a missense mutation in 
Muc2.  The signage for a mutation is m. Homozygous mice designated m/m show 
symptoms closely resembling inflammatory bowel disease. The colony is normally 
maintained as heterozygous m/+ x m/+. The Winnie mouse model was utilized 
because the gene deficiency in Muc2 causes the depletion of the mucin glycoprotein 
that forms a thick protective layer over the colonic epithelium and renders the mice 
susceptible to pathogenic microbial penetration into the colonic mucosal system. 
Pathogenic microbial assault and the influence of the CCR6-CCL20 axis in the 
intestines are regarded as substantial causes of developing chronic colitis in mouse 
models (40). Winnie mice develop chronic spontaneous colitis by 6 weeks of age (and 
mimics clinical UC), and the disease pathology advances with age.  
3.1.3 Ccr6 -/- mice (Winnie +/+, Ccr6-/-) 
These mice are on the C57BL/6J parental background in which the Ccr6 gene has been 
knocked out. The genotype is Ccr6 -/-.   The signage -/- designates a knockout. This is 
a homozygous strain and has been maintained in the facility as a homozygous colony. 
CCR6 -/- males are mated with CCR6 -/- females to produce the CCR6 -/- offspring. 
These mice do not carry the Winnie mutation. These mice are deficient for Ccr6 and 
yet, do not display any gut-associated clinical symptoms. These mice have normal 
Muc2 expression and were deficient in the CCR6 protein. This group of mice were 
denoted by the Winnie +/+, Ccr6-/- genotype.  
3.1.4 Winnie x Ccr6-/- mice (m/m, Ccr6-/-) 
The experimental model, derived from Winnie and CCR6 mice (Figure 5), thus named 
Winnie x Ccr6-/-, develops the disease (spontaneous colitis) due to the absence of 
mucin and because it was also CCR6 deficient, we hypothesised these mice to have 




3.2 Pre-clinical parameters indicate that Ccr6-deficiency reduces 
inflammation in the colon. 
3.2.1 Colon length 
Table 13. The mean colon length (cm) in the genotypes at both timepoints. 
 WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 8.4 + 0.14 cm 8.4 + 0.25 cm 8.2 + 0.25 cm 8.6 + 0.25 cm 
16-22 
weeks 
8.0 + 0.11 cm 8.6 + 0.27 cm 9.3 + 0.15 cm 9.7 + 0.25 cm 
 
A significant difference in colon length exists between WT and Winnie (***p<0.001) as 










































































              
Figure 6.  Comparison of the lengths of freshly removed colons measured from the 
ileo-caecal junction to the anus in the four genotypes. Data expressed as mean + SEM 
by one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test, n=8, 




 3.2.2 Colon weight 
Table 14. The mean colon weight (g) in the genotypes at both timepoints. 
 WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 0.15 + 0.01 g 0.15 + 0.01 g 0.29 + 0.03 g 0.36 + 0.01 g 
16-22 
weeks 
0.1 3+ 0.01 g 0.65 + 0.03 g 0.53 + 0.03 g 0.55 + 0.1 g 
A significant difference in the colon weight was observed between Winnie x Ccr6-/- 
and Winnie (*p< 0.05) at the first timepoint and  between WT and Winnie x Ccr6-/- 
(****p< 0.0001) and between WT and Winnie (****p< 0.0001) at both timepoints (Table 
14, Figure 7).  



















































































Figure 7. Comparison of wet colon weight after removing the luminal contents in 
the four genotypes. Data expressed as mean + SEM by one-way analysis of variance 
(ANOVA) and Tukey’s multiple comparison test, n=8. (A) at 8 weeks of age (B) at 16-




3.2.3 Colon Weight /Colon Length Ratio 
Table 15. The mean colon weight/ length (g/cm) ratio in the genotypes at both 
timepoints. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 0.018 + 0.003 0.018 + 0.002 0.036 + 0.01 0.041 + 0.004 
16-22 
weeks 
0.01 + 0.003 0.07 + 0.01 0.05 + 0.01 0.06 + 0.01 
The colon weight/colon length ratio was significantly increased between WT and 
Winnie x Ccr6-/- (****p<0.0001) and between WT and Winnie (****p<0.0001) at both 
timepoints (Table 15, Figure 8). 



































































































Figure 8. Comparison of the colon weight/length ratio in the four genotypes. Data 
expressed as mean + SEM by one-way analysis of variance (ANOVA) and Tukey’s 






3.2.4 Body Weight 
Table 16. The mean body weight (g) in the genotypes at both timepoints. 
            
 
WT  
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 26.2 + 0.35 20.46 + 0.6 20.15 + 0.68 16.95 + 0.82 
16-22 
weeks 
24.64 + 0.33 22.35 + 0.2 24.60 + 0.17 19.97 + 0.04 
 
A significant difference was evident in the mean body weight between the WT and 
Winnie (****p<0.0001) and between WT and Winnie x Ccr6-/- (****p<0.0001) at both 
timepoints and between Winnie x Ccr6-/- and Winnie (****p<0.0001) at the second 
timepoint (Table 16, Figure 9).   















































































Figure 9. Comparison of body weight in the four genotypes. Data expressed as mean 
+ SEM by one-way analysis of variance (ANOVA) and Tukey’s multiple comparison 





3.2.5 Colon Weight/Body Weight Ratio 
Table 17. The colon weight/body weight in the genotypes at both timepoints. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 0.006 + 0.001 0.007 + 0.001 0.017 + 0.005 0.018 + 0.002 
16-22 
weeks 
0.007 + 0.001 0.026 + 0.003 0.023 + 0.005 0.03 + 0.004 
 
A significant difference was evident in the colon weight /body weight ratio between 
the WT and Winnie (****p<0.0001) and between WT and Winnie x Ccr6-/- 
(****p<0.0001) at both timepoints (Table 17, Figure 10).   


































































































Figure 10. Comparison of colon weight/body weight ratio in the four genotypes. 
Data expressed as mean + SEM by one-way analysis of variance (ANOVA) and 





3.2.6 Gross Colon Morphology  
Table 18. Gross colonic morphological features after the removal of the colon. 
 Genotype  Observation 
WT Faecal pellets were well -formed, solid and hard with no 
symptoms of inflammation, narrow short colon with thin bowel 
wall (Table 18, Figure 11 A, B). 
Ccr6-/- Semi-solid faeces in the proximal colon, faecal pellets formed in 
the distal colon, mild inflammation, slightly oedematous bowel 
wall (Table 18, Figure 11, C, D). 
Winnie x Ccr6-/- Semi-solid faeces in the proximal colon, faecal pellets formed in 
distal colon, mild inflammation, mildly thickened bowel wall 
(Table 18, Figure 11 E, F). 
Winnie  Watery stools, faecal pellets not formed, high inflammation, 
thickened, reddened and oedematous bowel wall (Table 18, 
Figure 11 G, H).  
 












     WT - 8weeks                         WT -16-22weeks 
 
Figure 11. Comparison of gross colon morphology. Freshly removed colons 
measured from the ileo-caecal junction to the anus in the four genotypes at 8 weeks of 












3.2.7 Disease Activity Index 
The disease activity index (DAI) in the four genotypes was assessed as per the criteria 
given in Table 19. 










WT Normal (25 
g) 
Absent Absent Absent 0 – No 
inflammation 
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Figure 12. The overall mean DAI score in the four genotypes tested. Data expressed 
as mean + SEM by one-way analysis of variance (ANOVA) and Tukey’s multiple 
comparison test, n=8. 
3.3 Ccr6-deficiency displayed attenuated inflammation in multi-
system pathology concomitant with colitis. 
3.3.1 Colon Histology 
Table 20. Grading of colitis and scoring sheet for H&E sections (117).  
Criterion WT Ccr6-/- Winnie x Ccr6-/- Winnie  
Distribution of inflammation 0 0 1 2 
0=None     
1=Focal     
2=Multifocal     
Depth of inflammation 0 0 1 3 
1=Mucosal     
2=Submucosal     
3=Transmural     
Lamina propria neutrophils     
0=None 0 1 3 3 
1=1-10     
2=11-20     
3=>20     
Cryptitis 0 0 1 1 
0=No cryptitis     
1=Cryptitis     
Crypt abscess 0 0 1 3 
50 
 
0=None     
1=1-5     
2=6-10     
3=>10     
Goblet cell loss 0 0 1 3 
0=Normal or <10%loss     
1=10-25%     
2=25-50%     
3=>50%     
Crypt architecture 0 1 1 3 
0=Normal     
1=Mildly irregular     
2=Moderate     
3=severe     
Ulceration 0 0 1 2 
0=None     
1=Superficial     
2=Deep     

























































































Figure 13. (a) Representative images of H&E colon histomorphology in the 
genotypes at 16-22 weeks of age. Arrows indicate (A) mucus filled goblet cells inside 
short crypts in Ccr6-/-, (B) moderately elongated crypts in Winnie x Ccr6-/-, (C) mucus 
filled goblet cells in Winnie x Ccr6-/-, (D) crypt abscess in Winnie, (E) highly elongated 
crypts in Winnie, (F) mucosal ulcerations in Winnie. No inflammation in WT and Ccr6-
/- while moderate inflammation existed in Winnie x Ccr6-/-. Severe inflammation was 
evident in Winnie. Magnification x40, x100, x200 and x400. (b) Quantification of 
inflammation in the colon in the four genotypes at 16-22 weeks of age using the 
histopathological score given in Table 20. Data expressed as mean + SEM by one-way 
analysis of variance (ANOVA) and Tukey’s multiple comparison test, n=8.  
3.3.2 Validation of mucin production by goblet cells in the colonic 
epithelium  
(a)       (b) 
  













































Figure 14. (a) The validation of mucin produced by the goblet cells within the 
colonic epithelium which makes the gut mucosa inaccessible to infectious 
microbes. Arrow points to a representative image of mucin stained with Alcian blue 
within the colonic epithelium of Winnie x Ccr6-/-. (x200), (b) the mean percentage (%) 
expression of mucin glycoprotein quantified by Fiji image J software. Percentage 
expression of intensity was calculated by the formula; optical density (OD) = log 
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(maximum intensity/mean intensity), where max intensity = 255 for 8-bit images using 
Fiji Image J Version 1.64 software for windows 7 (Scijava Software Inc, USA).  Data 
expressed as mean + SEM by one-way analysis of variance (ANOVA) and Tukey’s 
multiple comparison test, n=8.  
3.3.3 Spleen weight 
Table 21. The mean spleen weight (g) in the genotypes at both timepoints.  
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 0.07 g + 0.004 0.066 g + 0.002 0.082 g + 0.01 0.09 g + 0.01 
16-22 
weeks 
0.09 g + 0.01 0.11 g + 0.003 0.12 g + 0.01 0.14 g + 0.01 
A significant difference in mean spleen weight existed between WT and Winnie 
(*p<0.05) and between WT and Winnie x Ccr6-/- (*p<0.05) at the first timepoint. At the 
second time point, there were significant differences between WT and Winnie 
(****p<0.0001), WT and Winnie x Ccr6-/- (*p<0.05) and Winnie x Ccr6-/- and Winnie 
(*p<0.05) (Table 21, Figure 15). 
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Figure 15. Comparison of the mean splenic weight in the 4 genotypes. Data 
expressed as mean + SEM by one-way analysis of variance (ANOVA) and Tukey’s 
multiple comparison test, n=8. (A) at 8 weeks of age (B) at 16-22 weeks of age.  
3.3.4 Spleen Histology 
Table 22. Spleen Histology Scoring System (118). 
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Figure 16. (a) Representative images of H&E spleen histology in the four genotypes 
at 16-22 weeks of age. Paraffin embedded haematoxylin and eosin (H&E) stained 
sections at x40, x100, x200 and x400 magnification. Arrows indicate (A) 
megakaryocyte, (B) neutrophils in Ccr6-/-, (C) neutrophils in Winnie x Ccr6-/-, (D) 
x40 x40 x40 x40 
x100 x100 x100 
x100 
x200 x200 x200 x200 









neutrophils in Winnie, (E) red pulp, (F) white pulp. (b) Quantification of inflammation 
in the spleen in the four genotypes at 16-22 weeks of age using the histopathological 
score given in Table 22. n=8.  
Inflammation was quantified in the genotypes by counting the numbers of immune 
cell infiltrations in 3 similar areas on the slides and comparing the mean value using 
a scoring index from 0 – 3, from no inflammation (score of 0) to severe neutrophil 
infiltration (score of 3), where WT was zero, Ccr6-/- was 1, Winnie x Ccr6-/- was a 
moderate 2 and Winnie had a score of 3.  
3.3.5 Liver Weight 
Table 23. The mean liver weight (g) in the genotypes at both timepoints.  
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 1.275 + 0.04 g 1.115 + 0.1 g 0.962 + 0.1 g 1.21 +0.1 g 
16-22 
weeks 
0.986 + 0.03 g 1.196 + 0.1 g 1.48 + 0.1 g 1.53 + 0.1 g 
 
The differences in the mean liver weight among the genotypes at the first time point 
were not significant [Table 23, Figure 17 (A)]. Significant differences existed between 
WT and Winnie x Ccr6-/- (****p< 0.0001), WT and Winnie (****p < 0.0001), and Ccr6-/- 















































































                     
Figure 17. Comparison of liver weight in the four genotypes. Data expressed as mean 
+ SEM by one-way analysis of variance (ANOVA) and Tukey’s multiple comparison 
test, n=8. (A) at 8 weeks of age (B) at 16-22 weeks of age. 
3.3.6 Liver Histology 
Table 24. Liver Histology Scoring System (118). 
Criterion WT Ccr6-/- Winnie x Ccr6-/- Winnie  
Steatosis Absent Absent Absent Absent 
Micro and 
Macro vesicles 
Absent Absent Absent Absent 
Cytoplasmic 
degeneration 
Absent Absent Absent Absent 
Necrotic foci Absent Absent Absent Absent 
Kupffer Cell 
activation 
Absent Absent Absent Absent 
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Figure 18. (a) Representative images of H&E in liver histology in the four genotypes 
at 16-22 weeks of age. Arrows indicate (A) portal tract, (B) central canal, (C) immune 
cell infiltration indicative of focal lobular inflammation in Winnie x Ccr6-/-, (D) severe 
focal lobular inflammation in Winnie at 16-22 weeks of age. (A) at 8 weeks of age (B) 
at 16-22 weeks of age. Inflammation was quantified in the genotypes by counting the 
numbers of immune cell infiltrations which indicate sporadic focal lobular 
inflammation in 3 similar areas on the slides and comparing the mean value using a 
scoring index from 0 – 3, from no inflammation to severe neutrophil infiltration, where 
WT was zero, Ccr6-/- was 1, Winnie x Ccr6-/- was a moderate 2 and Winnie had a score 
of 3. (b) Quantification of inflammation in the liver in the four genotypes at 16-22 
weeks of age using the overall mean histopathological score given in Table 24. Data 
expressed as mean + SEM by one-way analysis of variance (ANOVA) and Tukey’s 







3.3.7 Kidney Weight 
Table 25. The mean kidney weight (of both kidneys together) (g) in the genotypes 
at both timepoints. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 0.362 + 0.01 g 0.294 + 0.02 g 0.275 + 0.03 g 0.4 + 0.01 g 
16-22 
weeks 
0.29 + 0.01 g 0.34 + 0.02 g 0.36 + 0.02 g 0.42 + 0.03 g 
A significant difference existed in the mean kidney weight between Ccr6-/- and 
Winnie (**p < 0.01), Winnie x Ccr6-/- and Winnie (***p < 0.001) and WT and Winnie x 
Ccr6-/- (***p < 0.001) at the first timepoint [ Table 25, Figure 19 (A)]. A significant 
difference also existed between WT and Winnie (***p <0.001) at the second timepoint 
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Figure 19. Comparison of kidney weight in the four genotypes. Data expressed as 
mean + SEM by one-way analysis of variance (ANOVA) and Tukey’s multiple 
comparison test, n=8. (A) at 8 weeks of age (B) at 16-22 weeks of age.  
3.3.8 Kidney Histology 
Table 26. Kidney Histology Scoring System (118). 
Criterion WT Ccr6-/- Winnie x Ccr6-/- Winnie  
Diminished/Distorted 
Glomeruli 
Absent Absent Absent Absent 
Dilated Tubules Absent Absent Absent Absent 
Oedema Exudate Absent Absent Absent Absent 
Mild Necrosis Absent Absent Absent Absent 
Infiltration of 
Inflammatory Cells 
Absent Absent Absent Absent 
Histology 
Inflammation Score 



























Figure 20. Representative images of H&E stained renal histology of the four 
genotypes, at magnification x40, x100, x200 and x400.  No renal pathology was 
detected as per criteria in Table 26. Quantification of inflammation in both kidneys 
in the four genotypes at 16-22 weeks of age was made using the histopathological 
score given in Table 26 which yielded zero inflammation in all the genotypes tested. 
(A) Kidney tubule (B) Glomerulus. Data expressed as mean + SEM by one-way 
analysis of variance (ANOVA) and Tukey’s multiple comparison test, n=8. 
3.4 Ccr6-deficiency reduces the lymphocyte distribution in the Spleen 
and MLN during colitis. 
3.4.1 Gating Strategy 
The gating strategy and dot plots used to quantify the lymphocyte percentages in the 
four genotypes in the spleen is displayed in Figure 21. In order to investigate the 














































relative distribution of T and B lymphocytes in the spleen, the percentages of the major 
surface markers (CD4+, CD8+ and CD19+), were quantified by flow cytometry.  
 
A B 
     
C  D        
                
 
Figure 21. Flow cytometry evidence showing the gating strategy and the dot plots 
for obtaining the surface marker percentages. Quantification of CD4+, CD8+, CD19+ 
percentage in 1 mL of splenocytes and MLN in the four genotypes at 8 and 16-22 
weeks of age. (A) after gating the lymphocytes on FSC-A vs SSC-A axes (B) singlet cell 
population on FSC-H vs FSC-A axes, to discriminate against the doublets, (C) CD4+% 
gated in red, CD8+ % gated in maroon, and (D) CD19+ % gated in blue. Over 95% of 




3.4.2 T (CD4+ & CD8+) and B (CD19+) Lymphocyte Distribution in the 
Spleen 
Table 27. CD4+ T lymphocyte mean percentage in the spleen. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 12.3 + 0.8 13.55 + 0.7 11.87 + 0.5 12.7 + 1.1 
16-22 
weeks 
10.72 + 0.6 10.86 + 0.6 9.21 + 0.6 8.6 + 0.7 
The differences between the splenic CD4+ mean percentages were not significant at 
both timepoints (Table 27, Figure 21-22). 
Table 28. CD8+ T lymphocyte mean percentage in the spleen. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 7.93 + 0.7 8.63 + 0.53 6.83 + 0.8 7.98 + 0.8 
16-22 
weeks 
6.24 + 0.3 6.38 + 0.17 4.1 + 0.22 4.22 + 0.6 
The differences in splenic CD8+ mean percentages between the genotypes tested were 
not significant at the first timepoint. There were significant differences between WT 
and Winnie (***p <0.001) and WT and Winnie x Ccr6-/- (***p <0.001) at the second 







Table 29. CD19+ (B lymphocyte) mean percentages in the spleen. 
 WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 37.87 + 2.98 47.33 + 2.0 43.51 + 1.75 34.97 + 2.37 
16-22 
weeks 
35.83 + 1.4 51.42 + 1.17 26.97 + 1.7 28.0 + 2.0 
The differences in the splenic CD19+ mean percentages between the genotypes were 
significant between WT and Ccr6-/- (*p < 0.05) and Ccr6-/- and Winnie (**p < 0.01) at 
the first timepoint. There were significant differences between WT and Ccr6-/- (****p 
<0.0001), Ccr6-/- and Winnie x Ccr6-/- (****p <0.0001), WT and Winnie (**p < 0.01) and 
Ccr6-/- and Winnie (****p < 0.0001) at the second timepoint (Table 29, Figure 21-22).  





























































































































































































































Figure 22. Quantification of splenic CD4+, CD8+ and CD19+ mean percentages in the 
four genotypes at 8 weeks of age [(A)(i), (A)(ii), (A)(iii) and at 16-22 weeks of age 
(B)(i), (B)(ii), (B)(iii). Spleens harvested in ice-cold PBS, RBC lysis buffer added to cell 
suspension, washed and suspended in FACS staining buffer. 2 x 107 cells per x1 mL 
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was stained with fluorescent-conjugated antibodies (CD4 – Brilliant violet 421, CD8 – 
Alexa fluor 488, CD19- PE and live/dead cell marker -IR 638) for 30 minutes on ice in 
the dark, washed and suspended in 200 µl of FACS buffer and analysed in a BD Canto 
FACS analyser with compensation and fluorescent minus one (FMO) controls. After 
gating the singlet cell population on FSC-H vs FSC-A axes, CD4% gated in red, CD8 
% gated in maroon and CD19% gated in blue were quantified to discriminate against 
doublets. Over 95% of the cell population remained viable at point of analysis. Data 
expressed as mean + SEM by one-way analysis of variance (ANOVA) and Tukey’s 
multiple comparison test, n=8. (* p< 0.05, **p<0.01, ***p<0.001, ****p< 0.0001). 
3.4.3 T (CD4+ & CD8+) and B (CD19+) Lymphocyte Distribution in the 
Mesenteric Lymph Nodes (MLN) 
Table 30. CD4+ (T lymphocyte) mean percentages in the MLN. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 10.7 + 0.24 14.04 + 0.1 6.56 + 0.23 16.3 + 0.4 
16-22 
weeks 
4.66 + 0.04 30.77 + 0.44 22.19 + 1.1 22.94 + 0.1 
 
The differences in the MLN CD4+ mean percentages between the genotypes were 
significant between WT and Winnie x Ccr6-/- (*p < 0.0001) and Ccr6-/- and Winnie (**p 
< 0.001) at the first timepoint. There were significant differences between WT and 
Ccr6-/- (****p < 0.0001), WT and Winnie x Ccr6-/- (****p <0.0001), WT and Winnie (**p 
< 0.0001) and Ccr6-/- and Winnie (****p < 0.0001) at the second timepoint (Table 30, 






Table 31. CD8+ (T lymphocyte) mean percentages in the MLN. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 13.23 + 0.2 6.85 + 0.13 5.35 + 0.4 15.8 + 0.3 
16-22 
weeks 
 3.65 + 0.02 15.74 + 0.6 14.87 + 0.4 18.38 + 0.5 
 
The differences in the MLN CD8+ mean percentages between the genotypes were 
significant between WT and Winnie x Ccr6-/- (****p < 0.0001) and Ccr6-/- and Winnie 
(****p < 0.001) and Winnie x Ccr6-/- and Winnie (****p <0.0001). There were significant 
differences between WT and Winnie x Ccr6-/- (****p <0.0001), WT and Winnie (**p < 
0.0001) and Winnie x Ccr6-/- and Winnie (**p < 0.001) at the second timepoint (Table 
31, Figure 21,23).  
 
Table 32. CD19+ (B lymphocyte) mean percentages in the MLN. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 13.2 + 0.25 17.1 + 0.35 7.0 + 0.36 17.92 + 0.36 
16-22 
weeks 
4.31 + 0.12 34.18 + 0.12 37.69 + 0.9 39.65 + 0.75 
The differences in the MLN CD19+ mean percentages between the genotypes were 
significant between WT and Winnie x Ccr6-/- (*p < 0.0001), WT and Winnie (*p < 
0.0001) at the first timepoint. There were significant differences between WT and Ccr6-
/- (****p < 0.0001), WT and Winnie x Ccr6-/- (****p <0.0001), WT and Winnie (**p < 


































































































































































































































































Figure 23. Quantification of MLN CD4+, CD8+ and CD19+ mean percentages in the 
four genotypes at 8 weeks of age [(A)(i), (A)(ii), (A)(iii) and at 16-22 weeks of age 
(B)(i), (B)(ii), (B)(iii). Pooled MLN were harvested and stored in ice-cold RPMI 1640 
culture medium (Life Technologies Pty Ltd, Victoria, Australia), washed and 
suspended in FACS staining buffer. 2 x 107 cells per x1 mL was stained with 
fluorescent-conjugated antibodies (CD4 – Brilliant violet 421, CD8 – Alexa fluor 488, 
CD19- PE and live/dead cell marker -IR 638) for 30 minutes on ice in the dark, washed 
and suspended in 200 µl of FACS buffer and analysed in a BD Canto FACS analyser 
with compensation and fluorescent minus one (FMO) controls. After gating the singlet 
cell population on FSC-H vs FSC-A axes, CD4+ % gated in red, CD8+ % gated in maroon 
and CD19+ % gated in blue were quantified to discriminate against doublets. Over 95% 
of the cell population remained viable at point of analysis, (n=3 independent 
experiments in duplicate for MLN). Data expressed as mean + SEM by one-way 
analysis of variance (ANOVA) and Tukey’s multiple comparison test. (* p< 0.05, 
**p<0.01, ***p<0.001, ****p< 0.0001). 
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3.5 Ccr6-deficiency downregulates CCL20 and PI3KP, upregulates AktP 
in the colon. 
3.5.1 CCL20 expression pattern in the colon. 
Table 33. CCL20 percentage expression in the colon at the second timepoint.  
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
16-22 
weeks 
0.006 + 0.0003 0.012 + 0.0003 0.014 +   0.0003 0.015 + 0.0003 
A significant difference in the CCL20 percentage expression in the colon existed 
between WT and Winnie (****p <0.0001) and Winnie x Ccr6-/- and Winnie (*p < 0.05) 
at the second timepoint [Table 33, Figure 24 (a) A-D, b(i)]. 
3.5.2 Phosphorylated Phosphoinositide 3-kinase (PI3KP) expression 
pattern in the colon. 
Table 34. PI3KP percentage expression in the colon at the second timepoint.  
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
16-22 
weeks 
0.05 + 0.001 0.011 + 0.001 0.014 + 0.0003 0.03 + 0.001 
A significant difference in the PI3KP percentage expression in the colon existed 
between WT and Winnie (****p <0.0001) and Winnie x Ccr6-/- and Winnie (****p < 







3.5.3 Phosphorylated Akt (AktP) expression pattern in the colon. 
Table 35. AKTP percentage expression in the colon.  
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
16-22 
weeks 
0.007 + 0.0003 0.009 + 0.001 0.02 + 0.001 0.015 + 0.0003 
A significant difference in the AKTP percentage expression in the colon existed 
between WT and Winnie (****p <0.0001) and Winnie x Ccr6-/- and Winnie (****p < 
0.0001) at the second timepoint [Table 35, Figure 24(a) I-L b(iii)]. 
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Figure 24. Comparison of the CCL20 [Table 33, (a)(A-D), (b)(i)], phosphorylated 
PI3K [Table 34, (a) (E-H), (b)(ii)] and phosphorylated Akt [ Table 35, (a) (I-L), (b)(iii)] 
mean percentage expression pattern in the colon in the four genotypes at 16-22 
weeks. Arrow indicates brown colour which determines the presence of DAB 
chromogen bound to anti-CCL20 -anti-mouse primary antibody, anti-PI3KP - anti-
mouse primary antibody, anti-AktP - anti-mouse primary antibody respectively, 
magnified at x200. The mean percentage (%) expression of (b)(i) CCl20, (b)(ii) PI3KP 
and (b)(iii) AktP quantified by Fiji image J software. Percentage expression of intensity 
was calculated by the formula; optical density (OD) = log (maximum intensity/mean 
intensity), where max intensity = 255 for 8-bit images using Fiji Image J Version 1.64 
software for windows 7 (Scijava Software Inc, USA). Data expressed as mean + SEM 
by one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test, n=3 
independent experiments in duplicate.  (* p< 0.05, **p<0.01, ***p<0.001, ****p< 0.0001). 
   
3.6 Ccr6-deficiency suppress the TH1 and TH17 lymphocyte immune 
responses during colitis and upregulates IL-10. 
Table 36. The cytokine expression evaluated by RT-PCR, divided into respective 





TH1 TH2 TH17 Treg 
IFN-γ IL-4 IL-17A IL-10 
TNF-α IL-6 IL-23R  
IL-18 IL-13   
75 
 
3.6.1 TH1 cytokine mRNA expression in the colon. 
Table 37. Mean fold change expression of mRNA in IFN-γ normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 1.0 + 0 0.7 + 0.3 0.9 + 0.7 10.0 + 0.2 
16-22 
weeks 
1.0 + 0 2.0 + 0.1 3.0 + 0.2 3.0 + 0.2 
A significant difference in the mean fold change expression of mRNA in IFN-γ existed 
between Winnie x Ccr6-/- and Winnie (****p <0.0001) at the first timepoint and between 
the WT and Winnie (****p <0.0001) at both timepoints [Table 37, Figure 25 (A)]. 
Table 38. Fold change expression of mRNA in TNF-α normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 1.0 + 0 0.94 + 0.04 2.6 + 0.1 10 + 0.2 
16-22 
weeks 
1.0 + 0 1.0 + 0.2 3.3 + 0.1 4.7 + 0.3 
A significant difference in the mean fold change expression of mRNA in TNF-α 
existed between Winnie x Ccr6-/- and Winnie (****p <0.0001) at the first timepoint and 
between the WT and Winnie (****p <0.0001) at both timepoints [Table 38, Figure 25 
(A)]. 
Table 39. Fold change expression of mRNA in IL-18 normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 1.0 + 0 1.0 + 0.02 5.0 + 0.2 39.17 + 1.0 
16-22 
weeks 
1.0 + 0 12.0 + 0.2 5.0 + 0.23 12.3 + 0.4 
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A significant difference in the mean fold change expression of mRNA in IL-18 existed 
between Winnie x Ccr6-/- and Winnie (****p <0.0001), WT and Winnie (**** p< 0.0001) 
at both timepoints and between Ccr6-/- and both Winnie x Ccr6-/- and Winnie (****p 
<0.0001) at the first timepoint [Table 39, Figure 25 (A)] 
3.6.2 TH2 cytokine mRNA expression in the colon. 
Table 40. Fold change expression of mRNA in IL-4 normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 1.0 + 0 0.3 + 0.1 1.15 + 0.2 35.0 + 0.4 
16-22 
weeks 
1.0 + 0 0.5 + 0.1 5.6 + 0.4 8.0 + 0.2 
 
A significant difference in the mean fold change expression of mRNA in IL-4 existed 
between the WT and Winnie (****p <0.0001), WT and Winnie x Ccr6-/- (****p <0.0001) 
and between Winnie x Ccr6-/- and Winnie (****p <0.0001) at both timepoints [Table 40, 
Figure 25 (B)]. 
Table 41. Fold change expression of mRNA in IL-6 normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 1.0 + 0 0.4 + 0.02 3.0 + 0.12 9.0 + 0.2 
16-22 
weeks 
1.0 + 0 1.12 + 0.14 1.2 + 0.24 3.0 + 0.2 
 
A significant difference in the mean fold change expression of mRNA in IL-6 existed 
between the WT and Winnie (****p <0.0001) at both timepoints and Winnie x Ccr6-/- 
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and between Winnie x Ccr6-/- and Winnie (****p <0.0001) at the second timepoint 
[Table 41, Figure 25 (B)].  
Table 42. Fold change expression of mRNA in IL-13 normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 1.0 + 0 0.4 + 0.1 2.0 + 0.23 22.0 + 0.44 
16-22 
weeks 
1.0 + 0 1.1 + 0.14 4.0 + 0.3 5.0 + 0.2 
 
A significant difference in the mean fold change expression of mRNA in IL-13 existed 
between Winnie x Ccr6-/- and Winnie (****p <0.0001) at the first timepoint and between 
the WT and Winnie (****p <0.0001) at both timepoints [Table 42, Figure 25 (B)]. 
 
3.6.3 TH17 cytokine mRNA expression in the colon. 
Table 43. Fold change expression of mRNA in IL-17A normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie 
Mean + SEM  
8 weeks 1.0 + 0 1.13 + 0.14 2.5 + 0.3 35.0 + 0.5 
16-22 
weeks 
1.0 + 0 0.93 + 0.04 0.63 + 0.1 1.2 + 0.12 
A significant difference in the mean fold change expression of mRNA in IL-17A 
existed between the WT and Winnie x Ccr6-/- (****p <0.0001) and Winnie x Ccr6-/- and 





Table 44. Fold change expression of mRNA in IL-23R normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 1.0 + 0 0.3 + 0.01 1.0 + 0.5 62.0 + 0.3 
16-22 
weeks 
1.0 + 0 0.3 + 0.01 2.0 + 0.03 2.0 + 0.13 
 
A significant difference in the mean fold change expression of mRNA in IL-23R 
existed between the WT and Winnie x Ccr6-/- (****p <0.0001) and Winnie x Ccr6-/- and 
Winnie (****p <0.0001) at the second timepoint [Table 44, Figure 25 (C)].  
3.6.4 Anti-inflammatory (Treg) cytokine mRNA expression in the colon. 
Table 45. Fold change expression of mRNA in IL-10 normalized to WT. 
            
 
WT 
Mean + SEM 
Ccr6-/- 
Mean + SEM  
Winnie x Ccr6-/- 
Mean + SEM 
Winnie  
Mean + SEM  
8 weeks 1.0 + 0 2.0 + 0.1 1.0 + 0.2 70.0 + 1.5 
16-22 
weeks 
1.0 + 0 2.6 + 0.1 4.3 + 0.2 4.2 + 0.12 
A significant difference in the mean fold change expression of mRNA in IL-10 existed 
between the WT and Winnie x Ccr6-/- (****p <0.0001) and Winnie x Ccr6-/- and Winnie 







(A) TH1 Immune Response 




























































































































































































































































































































(B) TH2 Immune Response 
















































































































   






































































































































































































































(C) TH17 Immune Response 










































































































































































































































(D) Treg Immune Response 




















































































































Figure 25. Fold change in mRNA expression of (A) IFN-g, TNF-α, IL-18, (B) IL-4, IL-
6, IL-13, (C) IL-17A, IL-23R, (D) IL-10 at 8 weeks and 16-22 weeks. Cycle of threshold 
(CT) values were normalised to Gapdh and CT calculated using the method of 2-∆CT. 
Data expressed as mean + SEM by one-way analysis of variance (ANOVA) and 
Tukey’s multiple comparison test, n=3 independent experiments in duplicate. 
(**p<0.01, *** p<0.001, ****p<0.0001). 
 
4.0 Discussion 
The purpose of this investigation was threefold: (i) to identify the phenotype of 
Winnie x Ccr6-/-, a novel colitis mouse model, and to evaluate the immunological 
impact of Ccr6 gene deficiency, (ii) in multi-organ pathophysiology and (iii) it’s role 
in molecular signalling, during the manifestation of spontaneous chronic colitis.  The 
results of this study have demonstrated that CCR6 plays a pathogenic role during the 
development of chronic colitis. As a direct result of Ccr6-deficiency during the 
continuance of colitis in Winnie, the following salient features were observed: (i) 
distinct reduction of inflammation in the colon, spleen and liver; (ii) absence of renal 
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pathology; (iii) suppressed TH1, TH17 immune responses with upregulated TH2 and 
Treg immune responses in the colon; (iv) restrained production and egression of 
lymphocytes from the spleen; (v) high lymphocyte proliferation within the mesenteric 
lymph nodes; and (vi) increased production of CCL20 and phosphorylated Akt (AktP) 
with decreased production of phosphorylated PI3K (PI3KP) in the colon. 
 Both human and mice systems have provided evidence for the inflammatory role 
played by the CCR6-CCL20 axis in the progression and pathogenicity of several 
autoimmune disorders, as well as IBD (42).  Winnie x Ccr6-/- was derived from 
crossing littermates of Winnie mice (Figure 5), which were a male with m/m, Ccr6-/- 
and a female with m/m, Ccr6-/- which produced a double homozygous knockout 
(m/m and Ccr6-/- ) and all the mice groups investigated in this study were of C57BL/6J 
mouse (strain) background. The experimental model thus produced a similar but 
relatively less severe intestinal inflammation that mimics human colitis (119).  
The Winnie mouse model, as a tool which resembles chronic colitis  has multiple 
advantages in comparison to other contrived colitis models which include: (i) 
chemically induced models such as DSS and TNBS - induced colitis (which has no 
need to use toxic chemicals) (120), (121), (ii) adoptive T cell transfer induced colitis 
(induced in an artificial immune deficient system and lacks adaptive immunity) (108) 
and (iii) genetically engineered models of colitis (which show complete deficiency of 
immune functions) (122).  This is because, in Winnie x Ccr6-/-,  (i) the disease manifests 
as spontaneous colitis (123), (110); (ii) it mimics human UC (124); (iii) it doesn’t cause 
severe tissue damage (110); and (iv) it maintains an intact, normal immune system in 
comparison to T cell transfer models (110). Additionally, inflammation in Winnie 
naturally occurred at 6 weeks (124) and was found to progress with age by the present 
study.  
A gain in the colon weight is considered as a sign of increasing inflammation (Table 
14, Figure 7), however, it may have been due to either natural growth (as there was a 
difference of about 12 weeks between the first and second timepoints and the BMI was 
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not calculated), increased fat metabolism and/or concurrent inflammation. However, 
Ccr6 - deficiency appears to reduce fat metabolism as CCR6-expressing adipocytes are 
implicated in obesity (42). Although all the mice involved in this study were fed with 
the same diet, autoclaved water and were raised in a temperature and humidity 
controlled aseptic environment, they displayed varying growth rates and 
susceptibility to inflammation, which indicated differences in the gut microbiome, 
physiology and the genetic makeup. 
The body weight (Table 16, Figure 9) progressively decreased in Winnie owing to the 
developing inflammation because colitis takes full effect as early as 8 weeks of age.  
Winnie x Ccr6-/- did not lose weight to the same extent as Winnie and indicated 
subdued inflammation and suppression of weight - losing physiological mechanisms 
that were responsible for Winnie’s remarkable weight loss. In the experimental model, 
both the weight gain mechanisms and features of inflammation in the colon tissue 
such as, fluid retention, oedema, reddening, vasculature and tissue injury, were all 
moderate and reduced, than those of Winnie (Table 20, Figures 11, 13) (123).  
The physiological mechanisms which increased fat metabolism and inflammation 
because of ER or oxidative stress (due to misfolded protein response) may become the 
reasons for the significant weight increase in the colon and the loss of body weight 
observed in Winnie,  acting alongside impaired innate and adaptive immunity (125). 
All the mice in this study were fed with a normal chow diet which contained less than 
10% of saturated fat, since prolonged high fat diets (HFD) had induced low-grade 
chronic intestinal inflammation in mice. Diets high in saturated fat are a known risk 
factor in the development of human IBD (125). 
The gross colon morphology (Table 18, Figure 11), the moderate DAI (Table 19, Figure 
12), and the auxiliary inflammation that was visible in Winnie x Ccr6-/-, are further 
validated by its colon histology scores [Table 20, Figure 13 (b)] and the immunological 
(cytokine) profile (Figure 36) which may have arisen  from the loss of CCR6 – driven 
immune mechanisms in the Ccr6-deficient mice that were tested. All the pre-clinical 
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parameters described above lead to the conclusion that Ccr6 deficiency renders 
Winnie with reduced colitis.  
Our data is in complete agreement with the results obtained by several research 
groups that had utilised the Ccr6- deficient mouse systems. For example, Ccr6-
deficient mice induced by DSS had displayed reduced susceptibility to the disease (40) 
while TNBS - induced colitis was attenuated by blocking the release of CCL20 (126). 
The adoptive transfer of CCR6+ CD4 T cells into recipient recombination activation 
gene 2 (Rag2-/-) mice also caused aggravated disease (127).  
The CCR6-CCL20 axis plays a pivotal role in maintaining immune homeostasis in the 
gut (39). It produces immune tolerance against the plethora of infectious luminal 
microbes which penetrate the gut mucosa and simultaneously step up immunity 
against many other disease-causing secondary contributing factors. When the 
purported immune tolerance breaks down, the phenomenal TH17 Vs Treg imbalance 
paradigm comes into play either by increased multiplication of pro-inflammatory 
immune cells such as CCR6+TH17 and CCR6+TH1, or by immune mechanisms that 
suppress the production of FOXP3+ -induced CCR6+Treg cells (127). These 
mechanisms are empowered by CCR6 which mainly functions in the roles of directing 
T lymphocyte development and differentiation, and immune cell chemotaxis which 
stimulate a cascade of accessory molecules and cytokines in the colon.  
The attenuation of inflammation was corroborated by the colonic histomorphology 
[with increased goblet cell numbers (Figure 14] which stimulated an increased 
production of mucus) seen in the study model in comparison to Winnie [which has 
deficient mucus generation (Figure 14 (b)]. Features of acute disease histology were 
less prominent in Winnie x Ccr6 -/- with all the general criteria used in the assessment 
being markedly reduced, showing a milder inflammatory status which correlated well 
with the pre-clinical parameters.  
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In addition to having pathology within the gastrointestinal tract, IBD patients also 
exhibit secondary organ pathologies termed as extraintestinal manifestations (128). 
The spleen, liver and kidneys which are immune-related organs of secondary 
lymphoid origin were examined as the systemic diseases - hepatitis and glomerular 
nephritis stem within these organs, where CCR6 played a pivotal role in initiating 
inflammation (65), (129), (130), (131).  There was a significant difference in the 
histopathology scores and the recurring spread of inflammation in colon tissue 
between Winnie x Ccr6-/- and Winnie and the same trend was continued in spleen 
(Table 22, Figure 16) and liver (Table 24, Figure 18)  histopathological scores at the 
second time point (at 16-22 weeks of age) of this study. 
It is evident that inflammation in the colon also renders them with splenomegaly 
although the available literature on spleen weight is inconclusive because colitis had 
mostly induced hypo-splenism in colitis patients (132). Spleen size was not related to 
site or extent of disease, or to recurrence, but a wide variation of spleen size was seen 
within inflammatory bowel disease which suggests that more sophisticated tests of 
splenic function might show a closer correlation with disease patterns (133). 
Splenomegaly had resulted in Winnie mice probably because of inflammation in the 
colon during the late disease stage as the red pulp mostly contains lymphocytes, 
macrophages and a higher proportion of red blood cells (133).  
The liver weight (Table 23, Figure 17) indicated that inflammation in the gut was slow 
to spread to the liver via the gut-liver axis. Dissemination of inflammatory cells from 
the gut across the hepatic portal circulation did not appear to spread the inflammation 
in mice during early disease, as there was no infiltration of immune cells in the portal 
tracts, which was also confirmed by their liver histomorphology.   
A similar trend to the spleen weight variation was observed in the liver weight with a 
progressive weight increase from the WT to Winnie during the late disease stage. It is 
well known that hepatobiliary complications are associated with colitis in clinical 
investigations  (134) and similarly, infiltration of inflammatory cells were observed in 
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the liver histology specimens. The inflammation was more in Winnie compared to 
Winnie x Ccr6-/-, again confirming that Ccr6-deficiency could attenuate inflammation 
in the liver and there is dissemination of immune cells via the gut liver axis in Winnie 
mice during the late disease stage of colitis.  
Liver pathology ( Table 24, Figure 18) indicated significant lobular inflammation in 
Winnie with milder inflammation in the Ccr6-deficient Winnie (135). There are reports 
of concomitant hepatobiliary manifestations in IBD patients, the most common 
complication being primary sclerosing cholangitis (PSC) (136). Consistent with the 
mild inflammation seen in this study, there were no granulomas, hepatic abscesses, 
amyloidosis, and gallstones which are traditionally observed in CD or PSC and 
autoimmune hepatitis which are usually described in UC patients (136). One of the 
significant observations from this investigation was that Ccr6-deficiency serves to 
reduce the disease severity in the liver and spleen of the colitis-afflicted mice.  
The kidney weight (Table 25, Figure 19) showed significant differences which 
indicated impaired renal growth. However, renal histology scores (Table 26, Figure 
20) showed that the kidneys were free of inflammation in all the genotypes that were 
tested. In Winnie mice, colitis failed to induce any signs of renal infection or 
inflammation even at the second time point albeit there was evidence of worsened 
inflammation in Ccr6-deficient nephritic mice (65),  because, compared to their WT, 
Ccr6 -deficiency in  those mice had induced reduced infiltration of regulatory T cells 
(Treg cells) and TH17 cells but not the TH1 type into the kidney tissue (137).  
CCR6+ TH17 cells possess dual capability; of either transforming into anti-
inflammatory, Treg cells or remaining as the pro-inflammatory TH17.  This is a critical 
turning point in IBD immunopathogenesis which is ascribed to an imbalance of the 
TH17/Treg paradigm associated with disease resolution (138), (89). The quantification 
of TH17 and Treg cell subsets would have been more informative although it was 
considered as fitting beyond the scope of this study. The genetic resilience and 
impaired migratory capacity of immune cells to the kidneys also may have been the 
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reasons behind Winnie mice not becoming susceptible to renal disease even during 
the late stages of colitis.  
CD4+, CD8+ (T cells) and CD19+ (B cells) are major surface markers of the T and B 
lymphocyte repertoire in the spleen. A declining trend of CD4+, CD8+ and CD19+ 
immune cell percentages in the spleen was observed at the second time point in 
Winnie and Winnie x Ccr6-/- with the WT having the highest percentage of the T cells 
(Table 27-29, Figure 21-22).  
Heightened inflammation in Winnie could have caused an imbalance in the immune 
responses of T and B lymphocytes [probably within the TH1, TH2, TH17, Treg and the 
regulatory B cells (Breg) subsets] produced in the spleen because they are fewer in 
number.  The impact of Ccr6-deficiency on lymphocyte production in the spleen was 
to suppress the effector cell mobilization and cause dysfunctional lymphocyte 
egression from the spleen. FTY720, an inhibitor of the sphingosine 1 phosphate 
receptor (SIP1) agonist, has been shown to restrict CD4 T lymphocyte egression from 
lymph nodes during the disease course of allergic diarrhoea (139). Ccr6 - deficiency in 
Winnie perhaps produced similar SIP1 receptor inhibition reactivity resulting in 
diminished CD4 lymphocyte egression from the spleen during chronic colitis.   
The activated, effector T cells perpetuate inflammation in the gut and hence, cause 
tissue destruction in the gut-mucosal system (140). CD4+ T cells in the intestines of IBD 
patients were markedly high possibly owing to enhanced influx and activation with 
decreased apoptosis (141). Several gut-homing receptors such as CCR9 and α4β7 are 
selectively induced on T cells during their priming in intestinal inflamed sites (142).  
A study which had blocked the migration of activated leukocytes into the inflamed 
tissue by specific antibodies such as vedolizumab had appeared highly effective (140). 
Nevertheless, T cells remain the key players in IBD. Targeting either T-cell migration 
or the use of regulatory T cells appear to be the most promising T-cell -activated 
therapies in colitis (141). Hence Ccr6-deficiency which induced negative chemotaxis 
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of leukocytes may have contributed towards alleviation of inflammation in the colon 
(140), (143).  
Both immunodeficient SCID and Rag1-/- mice showed no disease development when 
given mature CD4+ CD45RB High T cells. The reason was that the donor cells consisted 
of regulatory T cells which up-regulated immune tolerance, and were present among 
the mature effector T cell population, whereas the recipient mice given either partially 
or naïve T cells developed a wasting disease (144).   
The present study has shown that Ccr6-deficiency serves to attenuate disease and 
plays a beneficial role owing to defective chemotaxis of proinflammatory immune 
cells with subsequent suppression of proinflammatory cytokines in the colon (Table 
37-39, Figure 25) (39).  However, the role played by CCR6 in an inflammatory setting 
remains obscure, because there are opposing arguments that CCR6-deficiency 
aggravates disease in mice having colitis (145). CCR6(+) Treg cells were characterized 
as antigen-activated and IL-10-producing in the steady-state, and preferentially 
migrated to the colon during inflammation to attenuate the severity of disease (146). 
A remarkable increase in splenic CD19+ (representing B lymphocytes) was observed 
during early disease in all the genotypes (Table 29, Figure 22). B-cell depletion has so 
far only been studied in ulcerative colitis where rituximab (anti-CD20) therapy had 
failed (143).  A study involving the distribution of regulatory B cells (CD5 + B cells) in 
the CD19 + CD3 - B cell population from blood and intestinal tissue during colitis, had 
recorded a significant decrease in the CD and UC patients than in the controls (147). 
Results of our study could be correlated with evidence that the pathogenesis of UC 
involves exhaustion of the regulatory B cell (Breg) cohort, resulting in a failure to 
control B cell activity (147). Thus, the results we have obtained suggest that improving 
regulatory B cell numbers and function may provide a complementary approach for 
the treatment of therapy-resistant UC (147). A separate study of B and T cell 
proliferation capacity needs to be carried out to further confirm high antigen 
sampling, priming of effector cells, immune responsivity and clonal selection in the B 
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and T cell groups, in the genotypes tested. A marked increase in B lymphocyte 
percentages in both the spleen and MLN during both early and late timepoints were 
observed in our study model which may have included the regulatory B cell 
component within our total B cell cohorts.  
Ccr6-deficiency acts to suppress the T and B lymphocyte expression in the MLN 
during early disease (Table 30-32, Figure 23). It may be that antigen sampling by the 
dendritic cells and macrophages which leads to the priming of effector lymphocytes 
is impaired by their inability to chemotactically migrate to the MLN. Notwithstanding 
the Ccr6- gene deficiency, which impaired chemotaxis of migratory immune cells and 
the T cell development and differentiation, the Ccr6-/- and Winnie x Ccr6-/- had 
produced an increase in T and B cell marker percentages between early and late 
disease stages and appeared to mount a combined, active, cellular and humoral 
immune response. They also displayed the capacity to respond to infections via T and 
B cell repertoires in the MLN, possibly indicating the ability to promote immune 
tolerance in a preclinical colitis setting.  
There was a significant increase in the TH1 cytokine mRNA expressions in Winnie 
(Table 37-39, Figure 25) which indicated severe inflammation and attenuation of 
disease in Winnie x Ccr6-/-, during the early timepoint. It is possible that a lowered 
TH1 immune response occurs owing to Ccr6- deficiency in Winnie mice and hence it 
acts to decrease the pro-inflammatory cytokine release in the colon tissue resulting in 
diminished inflammation. These differences may have resulted due to differences in 
pathogenesis, increased immune suppression mechanisms or the microbiota within 
the genotypes although they were littermates and were fed the same diet, housed in 
the same environment, but different cages. 
Results of our study indicate that Ccr6-deficiency does not heavily induce IFN-γ 
(Table 37) and TNF-α (Table 38) production during early inflammation in colitis, and 
at the second time point remains below than that of Winnie, is corroborated by 
published data which had revealed a robust production of IFN-γ in the gut of DSS-
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treated WT mice, associated with severe intestinal inflammation (148). Neutralization 
antibody against IFN-γ had partially but significantly ameliorated disease (149). IFN-
γ is also involved in regulating intestinal epithelial cell homeostasis, cell proliferation 
and apoptosis through converging beta- catenin signalling pathways (150), and 
activating the major histocompatibility complex class II (MHC II) on antigen-
presenting cells and non-immune cells (151).  
The beneficial attribute of IFN-γ is that it also bears anti-inflammatory properties that 
may be supported by the observations made at the latter time point in the present 
study. It was shown in a mouse model of Salmonella typhimurium- induced colitis, that 
animals lacking IFN-γ, the severity of intestinal inflammation was markedly 
attenuated (152). Conventionally, IFN-γ is produced during the innate immune 
response to bacterial infections by natural killer (NK) cells and NKT cells with both 
CD4+ and CD8+ T cells becoming the sources at later stages that are responsible for 
eliciting adaptive immune responses (152). Moreover, IFN-γ has been identified as a 
negative regulator of IL-23 – mediated experimental colitis (153). 
High levels of TNF-α in the intestinal mucosa is associated with the development of 
relapses and sustaining chronic inflammatory activity, which in our study model was 
conspicuously reduced. Intestinal homing of memory T lymphocytes were shown to 
augment TNF-α levels in relapsing UC patients along with higher NF-kB nuclear 
translocation in lamina propria mononuclear cells taken from IBD patients (154). 
According to Arora and Shen (2014), excessive production of TNF-α occurs from 
activated macrophages and T lymphocytes leading to further activation of 
macrophages and T cells as well as recruitment of neutrophils, culminating in a 
vicious cycle of heightened colonic inflammation (155).  
The targeted deletion of Nuclear Factor -kappa B essential modulator (NEMO), also 
known as IKK-γ mouse model, develops into colitis due to the lack of NF-kB pathway 
resulting in elevated sensitivity of colonic epithelial cells to TNF-α and apoptosis, 
causing spontaneous and severe chronic intestinal inflammation.  However, these 
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models lack the ability to represent the true immunogenicity of natural human colitis 
(156).  
A similar pattern was observed in the cytokine mRNA expression in TH2 cytokines 
(IL-4, IL-6 and IL-13; Table 40 -42) and TH17 cytokines (IL-17A and IL-23R; Table 43-
44). However, the anti-inflammatory cytokine, IL-10, mRNA expression (Table 45) 
was the lowest in Winnie x Ccr6-/- and was the highest in Winnie at 8 weeks.  Although 
IL-10 was produced in excess, during early disease, it did not seem to contribute to 
dampen the inflammation in Winnie. Although Winnie displays a high IL-10 
expression, and theoretically, it should promote colonisation of more Treg cells in the 
colon tissue, there seemed to be a different mechanism that determined the TH17/Treg 
imbalance in Winnie.  The suppressed IL-10 expression in Winnie x Ccr6-/- also did 
not appear to aggravate inflammation in the experimental model, either. It could be 
explained either by the absence of CCR6+ immune cells such as TH1, TH17 and/or 
Treg cells owing to defective migratory capacity to the colonic mucosa or there was 
upregulation of immune tolerance via regulatory T and B cells which served to curtail 
inflammation.     
The TH2 cells produce IL-4, IL-10 and IL-13 which are known to inhibit TH1-mediated 
immune responses  (157) those of which were evident in Winnie x Ccr6-/-. Published 
data reveal that the expression of IL-4 mRNA was reduced in IBD patients due to the 
loss of balance between proinflammatory and anti-inflammatory effects (158). IL-4 is 
mainly produced by activated lymphocytes and its main function is to inhibit 
formation of macrophage colonies (158). IL-4 causes a significant reduction in 
inflammation via suppression of vascular endothelial growth factor (VEGF) produced 
by peripheral blood mononuclear cells in patients having active CD and UC (157).  
IL-6 is involved in IBD pathophysiology as a proinflammatory cytokine and (157) and 
its level in the colon is correlated with disease severity (159).  Reportedly IL-6 acts to 
induce T and B cell differentiation, stimulating the survival and proliferation of 
intestinal epithelial cells, acute phase proteins in hepatocytes and maturation of 
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megakaryocytes (159). IL-6 had induced inflammation and epithelial homeostasis in 
the colon during chronic colitis (160). Increased IL-6 activity leads to upregulating the 
nuclear translocation of STAT3, which is important for the dichotomous TH17 or Treg 
imbalance paradigm which occurs in IBD and for maintaining anti-apoptotic activity 
in the lamina propria of the colon (161).   
IL-13 not only contributes to pathology but also mediates TH2-like immune responses 
(162). IL-13 can directly act on macrophages driving the differentiation towards the 
M2 phenotype (163). Ccr6- deficiency had increased IL-13 towards late disease 
compared to Winnie and the WT, and the biological effects of IL-13 demonstrate that 
it elicits a more favourable response in colitis. However, in Winnie, IL-13 immune 
mechanisms appeared to be upregulated with severity of disease.  
In our study, Ccr6-deficiency significantly induced a moderately high IL-10 mRNA 
expression (a 4-fold increase compared to the WT – Table 45, Figure 25) during the 
late stage of inflammation which had suppressed the inflammation in Winnie x Ccr6-
/-. IL-10 is an established anti-inflammatory cytokine produced by T cells, B cells and 
monocytes when stimulated by an antigenic stimulus. IL-10 is known to downregulate 
MHC II molecules which diminish the antigen presenting capacity of cells thus 
inhibiting the production of IL-6, interleukin -1 beta (IL-1β) and TNF-α (157).  
Similarly, IL-17A mRNA expression (Table 43, Figure 25) and  the IL-23R mRNA 
expression (Table 44, Figure 25) were moderately elevated in Winnie x Ccr6-/- at the 
second time point, indicating the priming of TH17+ immune cells, like that of Winnie. 
Since IL-23 is a natural stimulator of IL-17+ cells, Ccr6-deficiency in Winnie could be 
upregulating the TH17 expression from which a certain proportion of TH17 
lymphocytes are converted into Treg cells and hence act to reduce the inflammation 
in the gut, spleen and liver. CCR6 stimulates the phosphorylation of AKT leading to 
mTOR and STAT3 signalling which culminate in upregulating the IL-17A-driven 
CD4+ T helper cell differentiation into TH17 and Treg subsets and the simultaneous 
suppression of the FOXP3+ -triggered Treg activation (127).   
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Inhibition of IL-17 had exacerbated CD and weakened epithelial barrier integrity, thus 
exhibiting its potency for activating disease resolution. IL-23 inhibition had attenuated 
CD as well as promoting the development of the regulatory T cells (164). In another 
study, antibodies targeting IL-23 had ameliorated colitis (165). Results of our study 
are consistent with these observations. The protein encoded by the IL23R gene is a 
subunit of the receptor for IL23A/IL23. This protein pairs with the receptor molecule 
IL12RB1/IL12Rbeta1, and both are required for IL23A signalling and is associated 
constitutively with Janus kinase 2 (JAK2), and also binds to transcription activator 
STAT3 in a ligand-dependent manner (166). T cells, which mediate immune responses 
during disease, are influenced by multiple factors including the cytokine milieu, 
microbial species, metabolites and signalling molecules which end up determining the 
outcome of disease (167). 
Patients with UC or CD who have persistent chronic inflammation of the colon for 
more than 8 to 10 years are in a very high risk of developing metastatic colorectal 
cancer (CRC). Approximately 25 to 30% of patients with a history of pan-colitis for 
more than 30 years develop colorectal cancer, because of prolonged exposure of the 
colon to chronic inflammation. The tissue infiltrating pro-inflammatory cells are 
thought to drive the neoplastic changes in the inflamed colon leading to CRC (168). 
To understand the signalling pathways that cause inflammation in the colon tissue is 
critical for effective prevention and therapy of chronic inflammatory diseases. This 
study has therefore, explored the CCL20, PI3KP and AKTP activity in the colitis mouse 
models we had used.  
CCL20 is a known inflammatory bio marker in colitis (169). The percentage expression 
of CCL20 in colon tissue (Table 33, Figure 24) was lowest in the WT and highest in 
Winnie while Winnie x Ccr6-/- was intermediate at the second time point. A significant 
difference in CCL20 expression existed between Winnie x Ccr6-/- and Winnie towards 
late disease.  
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The PI3K / AKT pathway is active in cells infiltrating inflamed human colon tissue. 
This pathway sustains the recruitment of inflammatory cells through a positive 
feedback loop (168). A range of chemo-attractants activate G protein-coupled 
receptors (GPCRs) such as CCR6, receptor tyrosine kinases (RTKs) and Toll-like / IL-
1 receptors (TLR/IL1Rs) and initiate inflammation by activating PI3K (168). 
Knowledge of the cellular source of PI3K activity in healthy, inflamed tissues is 
therefore important for understanding how PI3K activity causes colitis and 
predisposes IBD patients to cancer. This knowledge will lead to understanding the 
mode of action of PI3K targeting drugs that are currently being tested for prevention 
and treatment of IBD.   
PI3KP is at the starting point of CCR6 receptor activation pathway (Figure 1) and 
hence, aids chemotactic navigation of lymphocytes and other CCR6 expressing cell 
types to the colon, during inflammation. The colonic PI3KP percentage expression in 
this study (Table 34, Figure 24) has indicated the suppression of chemotaxis in T and 
B lymphocytes to the gut and secondary lymphoid organs during colitis which have 
advantages as well as disadvantages. On one hand it appeared to promote cell 
mediated immune tolerance leading to tissue restitution  and on the other hand it 
upregulates the release of proinflammatory cytokines, free radicals, nitric oxide (NO), 
reactive oxygen species (ROS) and metabolites that caused oxidative stress and 
exacerbated inflammation in the gut (170). However, the lowered expression of PI3KP 
in colon tissue in the Ccr6-deficient mice could be helping in either early resolution of 
disease or to keep the inflammation contained. 
Ccr6-deficiency in Winnie induced downregulation of PI3KP expression in the colonic 
epithelial tissue. The CCR6-activation pathway is also stimulated by PI3KP which 
directs actin polymerisation leading to enhanced migratory capacity of CCR6-bearing 
immune cells. The PI3K/AKT/mTOR/PTEN signalling network plays an important 
role in metabolism and inflammation under physiological conditions. The effective 
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targeting of this signalling cascade with pharmacological modulators may also result 
in successful treatment of patients with inflammation (170).  
A study has reported the measuring of DAI and histological scores of mice after 
treatment with a PI3K inhibitor (Wortmannin), where both mice (with DSS colitis) and 
UC patients, showed a significant decrease in the DAI and tissue-morphology which 
suggested that  PI3K inhibition contributed towards attenuating colitis (171).  
However, this same study had shown a lowering of phosphorylated Akt alongside 
the declining DAI, although in the present study, Ccr6-deficiency had stimulated a 
significant increase in AktP (Table 45, Figure 24) compared to the WT and Winnie.  This 
indicates to us that phosphorylated Akt performs multiple roles in activating both 
beneficial and non-beneficial immune pathways in colitis and needs further 
investigation.  
AktP is a well- known biomarker in the CCR6-upregulated Akt-mTOR pathway which 
helps to determine the tilt of TH17/Treg imbalance that produces resolution of colitis 
(127). Akt, which is also known as Protein kinase B (PKB), is a serine/threonine-specific 
protein kinase that plays a key role in multiple cellular processes (Figure 26) such as; 
glucose metabolism, apoptosis, cell proliferation, transcription and cell migration 
(172). The Akt-stimulated glucose metabolism could aid  the tissue repair and 
restitution in the gut (173). The mild to moderate inflammation seen in Winnie x Ccr6-
/- could depend upon a different AktP-driven immune mechanism that is involved in 
colitis resolution. The Winnie x Ccr6-/-  produced elevated levels of phosphorylated 
Akt, which stimulates the Nuclear factor kappa beta (NF-kB) pathway, with a 
concomitant decrease in TNF-α production in the colon which probably had produced 
the low level of inflammation (154). Further investigation is needed to establish the 
contribution made by PI3KP and AktP during colitis in the four genotypes included in 
my study.  
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The limitations of my study include lack of functional studies on the immune cell 
repertoires and quantification of regulatory T cells and other T lymphocyte cohorts as 
well as detailed screening of the proteins involved in molecular signalling, which 
again was considered as beyond the scope of a Masters study.   
Recent genome wide association studies (GWAS) illustrated Ccr6 as a predisposing 
genetic locus in IBD patients, a mechanism by which CCR6 imparts immunological 
modulation. This study has highlighted a functional role for CCR6 in the 
pathogenicity of spontaneous chronic colitis and implies that CCR6 could be utilised 
as a functional therapeutic target in IBD.  The proven functional efficacy of CCR6-
inhibition (Table 46, Figure 3) in psoriasis, rheumatoid arthritis (RA), multiple 
sclerosis (MS), carcinoma and experimental autoimmune encephalitis (EAE), could be 
replicated in IBD as well (73). Recent research had shown the direct involvement of 
CCR6 with AKT/mTOR pathway which contributes to the TH17/Treg imbalance (that 
is considered as the prime immunological factor) and that it influences the resolution 
of colitis (127). In conclusion, it is proposed to further evaluate the potency of CCR6 - 




Figure 26. Some possible immune pathways involving PI3K and AktP. 
Legend: Phosphatidylinositol 4,5-bisphosphate (PIP2), Phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), Phosphatase and tensin homolog (PTEN), Phosphoinositide 3-
kinases (PI3K), 3-Phosphoinositide-dependent protein kinase 1 (PDK1), C-C 
Chemokine Ligand 20 (CCL20), C-C Chemokine Receptor 6 (CCR6), Guanine 
nucleotide binding proteins -alpha subunit (Gα), Guanine nucleotide binding protein 
– beta subunit (Gβ), Guanine nucleotide binding protein -gamma subunit (Gγ), 
Thrombospondin-1 (TSP1), Nitric oxide synthase (NOS),  Hypoxia-inducible factor 1-
alpha (HIF-1α), P38 Mitogen Activated Protein Kinases (p38 MAPK), Tuberous 
Sclerosis 1 (TSC1), Tuberous Sclerosis 2 (TSC2), Mammalian Target of Rapamycin 
(mTOR), Mammalian Target of Rapamycin Complex 1 (mTOR C1), Ribosomal Protein 
S6 Kinase beta - 1 (P70S6K), Phosphofructokinase -1 (PFK-1), Phosphofructokinase-2 
(PFK-2), Androgen Receptor (AR), Protein Kinase B (Akt), Phosphorylated Signal 
Transducer of Activation of Transcription 3 (STAT3P), Forkhead Box P3 (FOXP3), 
RAR-related orphan receptor gamma (t) (RORγt), Interleukin 17 A (IL-17A), Raf-1 
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Proto-Oncogene, Serine/Threonine Kinase (Raf-1), Inhibitor of Kappa B Kinases 
(IKKS), Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), 
Focal Adhesion Kinase in Integrin (FAK), Integrin-Linked Kinase (ILK), Janus kinase 
1 (JAK-1). 
5.0 Future Directions 
Further studies are required to gain deeper knowledge of the exact mechanisms of the 
CCR6–CCL20 axis. Extensive studies into immune and therapeutic functions of the 
CCR6–CCL20 axis with the use of novel inhibitors need to gain momentum, as there 
is a profound gap in immunological research into the treatment options for 
autoimmune and inflammatory disorders. New interventions with synthetic cellular, 
molecular, or nanoparticle inhibitors and derivatives of herbal and anti-toxic 
metabolites could be utilized to mimic or block the numerous biochemical pathways 
through which the CCR6–CCL20 axis is involved in disease promotion. Given the 
skewed immune regulation inducted by CCR6 and CCL20 partners in producing an 
imbalanced TH17 and Treg populations, which tilt immune homeostasis into 
inflammation, the invention of a vaccine may even become possible to boost T and B 
memory lymphocyte subsets of choice, coupled with selective inhibition of these two 
chemokines. Comprehensive randomized, placebo-controlled, clinical trials on the 
therapeutic use of the CCR6–CCL20 axis could become useful to thoroughly evaluate 
the benefits and disadvantages of using inhibitors of this axis, in humans. 
Most of the studies undertaken have utilized multiple animal models which may not 
be a true depiction of human colitis. Therefore, pre-clinical studies involving the 
relevant IBD animal models (spontaneous colitis) or human tissue (organoids and 
spheroids) would be preferable options. Investigations into novel paradigms such as 
ILC behaviour, ER stress, gut-specific microbiome, intestinal apoptosis, and 
metabolomics need to be encouraged with special reference to CCR6 mediation. Goal-
oriented, specifically targeted innovative research models are needed to construct the 
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broader context surrounding the CCR6–CCL20 immune modulation, which will open 
avenues to test more effective therapeutic interventions to treat IBD in the future. 
Preclinical models such as CCR6/CCL20 double knockouts as well as humanized 
murine clones and randomized clinical trials utilizing antibodies, novel CCR6 
inhibitors, and deeper investigation of TH22 cells associated with inflammatory 
response are suggested as future initiatives which might bring us closer to elucidating 
the immunogenic contributions of the chemokine receptor 6. Studies utilizing 
proteomics and metabolomics methodologies, combined with the CCR6 biology, may 
also be useful in identifying the multiple immune pathways that are dysregulated in 
IBD. A comparison of immune mechanisms with those delineated so far in other 
autoimmune disorders may also be useful, given the shared genetic and molecular 
etiologic factors. 
 The CCR6/CCL20 axis demonstrates a vital role in determining the disease outcome 
of inflammatory disorders and cancer metastasis in multiple organ systems in the 
human body (42). Effective blocking of the CCR6 signal transduction pathway using 
novel biochemical interventions (Figure 3) might prove to be a useful therapeutic 
strategy in regulating pro-disease - inducing cell chemotaxis within inflammatory 
microenvironments. Most of the research has been centred on animal models which 
do not depict the true clinical picture, and therefore there remains an urgent need for 
the evaluation of the chemokine receptor 6 and its ligand in expanded in vivo and ex 
vivo clinical studies. 
6.0 Conclusion 
Ccr6-deficiency in the Winnie mouse model indicated that it could potentially 
promote the immune mechanisms in the colon which augments attenuation of colonic 
inflammation during spontaneous chronic colitis. Ccr6-deficiency plays an important 
role in the pathogenesis of colon, spleen and liver during colitis by acting to lessen the 
severity of disease which involved these organs. It is indicated that the immune 
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activation pathways steered by phosphorylated PI3K and phosphorylated Akt 
possibly contribute to reduce inflammation in the gut in pre-clinical models. 
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8.1 Types of inhibitors used against the CCR6–CCL20 axis. 
 
Table 46. Types of inhibitors used against the CCR6–CCL20 axis, their common 
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Legend: MAPK—mitogen activated protein kinase, p—protein, CCL20—CC 
chemokine ligand 20, mAbs—monoclonal antibodies, BsAb—bispecific antibodies 
CCR6—CC chemokine receptor 6, hCCR6—humanised CCR6, Abs—antibodies, IL—
interleukin, TNF-α—tumor necrosis factor-alpha, BET—bromodomain extraterminal 
proteins, PO4—phosphate, R—receptor, RNA—ribonucleic acid, AOP-RANTES—
amino oxy pentane regulated on activation, normal T cell expressed and secreted. 
NK—natural killer, PBMC—peripheral blood mononuclear cells, IMQ—Imiquimod, 
TH17—T helper subset 17, Treg—regulatory T reg cell, γδ T cell—gamma delta T cell, 
EGCG—Epigallocatechin gallate, Ref—references to inhibitors, MS—multiple 







































8.2 Ethics Approval Permit 
Animal Ethics Committee 
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Office of Research Services 
Phone : 03 62266236 
Fax: 03 62267148 
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Project: A0017451 - Immune Profiling in a CCR6 Deficient Model of Spontaneous Inflammatory 
Bowel Disease 
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Please read this permit carefully as approval may be withdrawn 
for non-compliance with the conditions stated below. 
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application document is attached. The approval is subject to the review and AEC approval of 
an annual report which is due before the approval anniversary. Please note the due date in 
your diary. 
As the Responsible Investigator, you MUST ensure that: 
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Tasmanian Veterinary Surgeons Act 1987 and Veterinary Surgeons 
Regulations 2012. If the project involves a veterinary service or other 
animal service, it is your responsibility to contact the University 
Veterinarian to discuss the legal requirements of competency 
assessment. 
3. It is the responsibility of institutions and researchers to be aware of and 
conduct research in accordance with both general and specific legal 
requirements, wherever relevant 
117 
 
4. The University Veterinarian and the Animal Ethics Committee are 
promptly notified of any unexpected event which was not considered in 
the initial application and impacts on the welfare of any animal directly 
or indirectly involved in the project. 
5. You contact the University Veterinarian to advise when and where your 
experiments will be conducted. Sufficient notice needs to be given so 
that an inspection can be easily arranged. 
6. In the event of any unexpected death, you contact the University 
Veterinarian to perform an autopsy. 
7. A full record is maintained of all animals used in this project. If at any 
stage you anticipate the need to use additional animals this must be 
communicated to the committee before use. Using additional animals 
without AEC approval is a breach of your ethics permit. 
8. That all investigators complete the MyLo Animal Ethics Online Training 
module every three years. 
The project is approved for a maximum of 3 years. If the project is to continue past the 
expiry 
date, a new initial application will need to be submitted. 
If the investigation necessitates a Parks & Wildlife permit or other permits, you are required 
to send copies to animal.ethics@utas.edu.au before commencing work. 
Executive Officer 
Animal Ethics Committee 
University of Tasmania 
Animal Ethics Committee 
Ethics Number: A0017451 
Project Name: 
Immune Profiling in a CCR6 Deficient Model of 
Spontaneous Inflammatory Bowel Disease 
Chief Investigator: Associate Professor Raj Eri 
School: Health Sciences 
Person responsible 
for day-to-day care: 
Ethics start date: 05 September 2018 
Ethics approved to: 04 September 2021 
Emergency Contact:  
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